US Patent & Trademark Office
Patent Public Search | Text View

United States Patent	12390132
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Harper; Wesley Scott

Methods and systems for early signal attenuation detection and processing

Abstract

Provided are methods and apparatus for receiving sensor data from an analyte sensor of a sensor monitoring system, processing the received sensor data with time corresponding calibration data, outputting the processed sensor data, detecting one or more adverse conditions associated with the sensor monitoring system, disabling the output of the sensor data during the adverse condition time period, determining that the one or more detected adverse conditions is no longer present in the sensor monitoring system, retrieving the sensor data during the adverse condition time period, processing the retrieved sensor data during the adverse condition time period, and outputting the processed retrieved sensor data.

Inventors: **Harper; Wesley Scott (Alameda, CA)**

Applicant: **ABBOTT DIABETES CARE INC.** (Alameda, CA)

Family ID: **1000008762191**

Assignee: **ABBOTT DIABETES CARE INC. (Alameda, CA)**

Appl. No.: **17/682484**

Filed: **February 28, 2022**

Prior Publication Data

Document Identifier	Publication Date
US 20220287601 A1	Sep. 15, 2022

Related U.S. Application Data

continuation parent-doc US 17411154 20210825 US 11298056 child-doc US 17682484
continuation parent-doc US 17245719 20210430 US 11116431 20210914 child-doc US 17411154
continuation parent-doc US 16228910 20181221 US 11013431 20210525 child-doc US 17245719

continuation parent-doc US 15061774 20160304 US 10194844 20190205 child-doc US 16228910
continuation parent-doc US 13925694 20130624 US 9310230 20160412 child-doc US 15061774
continuation parent-doc US 12769635 20100428 US 8483967 20130709 child-doc US 13925694
us-provisional-application US 61173600 20090429

Publication Classification

Int. Cl.: **A61B5/145** (20060101); **A61B5/1473** (20060101); **A61B5/1495** (20060101); **G01D18/00** (20060101); **G01N31/22** (20060101); **G01N33/66** (20060101); **G16H40/40** (20180101)

U.S. Cl.:

CPC **A61B5/14532** (20130101); **A61B5/1473** (20130101); **A61B5/1495** (20130101); **G01D18/00** (20130101); **G01N31/22** (20130101); **G01N33/66** (20130101); **G16H40/40** (20180101);

Field of Classification Search

CPC: A61B (5/14532); A61B (5/1473); A61B (5/1495); G16H (40/40); G01D (18/00); G01N (31/22); G01N (33/66)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
3581062	12/1970	Aston	N/A	N/A
3926760	12/1974	Allen et al.	N/A	N/A
3949388	12/1975	Fuller	N/A	N/A
4036749	12/1976	Anderson	N/A	N/A
4055175	12/1976	Clemens et al.	N/A	N/A
4129128	12/1977	McFarlane	N/A	N/A
4245634	12/1980	Albisser et al.	N/A	N/A
4327725	12/1981	Cortese et al.	N/A	N/A
4344438	12/1981	Schultz	N/A	N/A
4349728	12/1981	Phillips et al.	N/A	N/A
4425920	12/1983	Bourland et al.	N/A	N/A
4441968	12/1983	Emmer et al.	N/A	N/A
4464170	12/1983	Clemens et al.	N/A	N/A
4478976	12/1983	Goertz et al.	N/A	N/A
4494950	12/1984	Fischell	N/A	N/A
4509531	12/1984	Ward	N/A	N/A
4527240	12/1984	Kvitash	N/A	N/A
4538616	12/1984	Rogoff	N/A	N/A
4619793	12/1985	Lee	N/A	N/A
4671288	12/1986	Gough	N/A	N/A
4703756	12/1986	Gough et al.	N/A	N/A
4731726	12/1987	Allen, III	N/A	N/A
4749985	12/1987	Corsberg	N/A	N/A

4757022	12/1987	Shults et al.	N/A	N/A
4759828	12/1987	Young et al.	N/A	N/A
4777953	12/1987	Ash et al.	N/A	N/A
4779618	12/1987	Mund et al.	N/A	N/A
4847785	12/1988	Stephens	N/A	N/A
4854322	12/1988	Ash et al.	N/A	N/A
4890620	12/1989	Gough	N/A	N/A
4925268	12/1989	Iyer et al.	N/A	N/A
4953552	12/1989	DeMarzo	N/A	N/A
4986271	12/1990	Wilkins	N/A	N/A
4995402	12/1990	Smith et al.	N/A	N/A
5000180	12/1990	Kuypers et al.	N/A	N/A
5002054	12/1990	Ash et al.	N/A	N/A
5019974	12/1990	Beckers	N/A	N/A
5050612	12/1990	Matsumura	N/A	N/A
5051688	12/1990	Murase et al.	N/A	N/A
5055171	12/1990	Peck	N/A	N/A
5082550	12/1991	Rishpon et al.	N/A	N/A
5106365	12/1991	Hernandez	N/A	N/A
5122925	12/1991	Inpyn	N/A	N/A
5135004	12/1991	Adams et al.	N/A	N/A
5165407	12/1991	Wilson et al.	N/A	N/A
5202261	12/1992	Musho et al.	N/A	N/A
5210778	12/1992	Massart	N/A	N/A
5228449	12/1992	Christ et al.	N/A	N/A
5231988	12/1992	Wernicke et al.	N/A	N/A
5246867	12/1992	Lakowicz et al.	N/A	N/A
5251126	12/1992	Kahn et al.	N/A	N/A
5262035	12/1992	Gregg et al.	N/A	N/A
5262305	12/1992	Heller et al.	N/A	N/A
5264104	12/1992	Gregg et al.	N/A	N/A
5264105	12/1992	Gregg et al.	N/A	N/A
5279294	12/1993	Anderson et al.	N/A	N/A
5285792	12/1993	Sjoquist et al.	N/A	N/A
5293877	12/1993	O'Hara et al.	N/A	N/A
5299571	12/1993	Mastrototaro	N/A	N/A
5320725	12/1993	Gregg et al.	N/A	N/A
5322063	12/1993	Allen et al.	N/A	N/A
5340722	12/1993	Wolfbeis et al.	N/A	N/A
5342789	12/1993	Chick et al.	N/A	N/A
5356786	12/1993	Heller et al.	N/A	N/A
5360404	12/1993	Novacek et al.	N/A	N/A
5372427	12/1993	Padovani et al.	N/A	N/A
5379238	12/1994	Stark	N/A	N/A
5384547	12/1994	Lynk et al.	N/A	N/A
5390671	12/1994	Lord et al.	N/A	N/A
5391250	12/1994	Cheney, II et al.	N/A	N/A
5394877	12/1994	Orr et al.	N/A	N/A
5402780	12/1994	Faasse, Jr.	N/A	N/A
5408999	12/1994	Singh et al.	N/A	N/A

5410326	12/1994	Goldstein	N/A	N/A
5411647	12/1994	Johnson et al.	N/A	N/A
5431160	12/1994	Wilkins	N/A	N/A
5431921	12/1994	Thombre	N/A	N/A
5462645	12/1994	Albery et al.	N/A	N/A
5472317	12/1994	Field et al.	N/A	N/A
5489414	12/1995	Schreiber et al.	N/A	N/A
5497772	12/1995	Schulman et al.	N/A	N/A
5507288	12/1995	Bocker et al.	N/A	N/A
5509410	12/1995	Hill et al.	N/A	N/A
5514718	12/1995	Lewis et al.	N/A	N/A
5531878	12/1995	Vadgama et al.	N/A	N/A
5552997	12/1995	Massart	N/A	N/A
5568806	12/1995	Cheney, II et al.	N/A	N/A
5569186	12/1995	Lord et al.	N/A	N/A
5582184	12/1995	Erickson et al.	N/A	N/A
5586553	12/1995	Halili et al.	N/A	N/A
5593852	12/1996	Heller et al.	N/A	N/A
5601435	12/1996	Quv	N/A	N/A
5609575	12/1996	Larson et al.	N/A	N/A
5628310	12/1996	Rao et al.	N/A	N/A
5640954	12/1996	Pfeiffer et al.	N/A	N/A
5653239	12/1996	Pompei et al.	N/A	N/A
5665222	12/1996	Heller et al.	N/A	N/A
5711001	12/1997	Bussan et al.	N/A	N/A
5711861	12/1997	Ward et al.	N/A	N/A
5726646	12/1997	Bane et al.	N/A	N/A
5735285	12/1997	Albert et al.	N/A	N/A
5748103	12/1997	Flach et al.	N/A	N/A
5771891	12/1997	Gozani	N/A	N/A
5772586	12/1997	Heinonen et al.	N/A	N/A
5791344	12/1997	Schulman et al.	N/A	N/A
5807375	12/1997	Gross et al.	N/A	N/A
5875186	12/1998	Belanger et al.	N/A	N/A
5899855	12/1998	Brown	N/A	N/A
5914026	12/1998	Blubaugh, Jr. et al.	N/A	N/A
5925021	12/1998	Castellano et al.	N/A	N/A
5942979	12/1998	Luppino	N/A	N/A
5951521	12/1998	Mastrototaro et al.	N/A	N/A
5954643	12/1998	VanAntwerp et al.	N/A	N/A
5957854	12/1998	Besson et al.	N/A	N/A
5961451	12/1998	Reber et al.	N/A	N/A
5964993	12/1998	Blubaugh, Jr. et al.	N/A	N/A
5965380	12/1998	Heller et al.	N/A	N/A
5971922	12/1998	Arita et al.	N/A	N/A
5972199	12/1998	Heller et al.	N/A	N/A
5987353	12/1998	Khatchatrian et al.	N/A	N/A
5995860	12/1998	Sun et al.	N/A	N/A
6001067	12/1998	Shults et al.	N/A	N/A
6004278	12/1998	Botich et al.	N/A	N/A

6022315	12/1999	Iliff	N/A	N/A
6024699	12/1999	Surwit et al.	N/A	N/A
6028413	12/1999	Brockmann	N/A	N/A
6049727	12/1999	Crothall	N/A	N/A
6052565	12/1999	Ishikura et al.	N/A	N/A
6066243	12/1999	Anderson et al.	N/A	N/A
6083710	12/1999	Heller et al.	N/A	N/A
6088608	12/1999	Schulman et al.	N/A	N/A
6091975	12/1999	Daddona et al.	N/A	N/A
6091976	12/1999	Pfeiffer et al.	N/A	N/A
6093172	12/1999	Funderburk et al.	N/A	N/A
6096364	12/1999	Bok et al.	N/A	N/A
6103033	12/1999	Say et al.	N/A	N/A
6117290	12/1999	Say et al.	N/A	N/A
6119028	12/1999	Schulman et al.	N/A	N/A
6120676	12/1999	Heller et al.	N/A	N/A
6121009	12/1999	Heller et al.	N/A	N/A
6121611	12/1999	Lindsay et al.	N/A	N/A
6122351	12/1999	Schlueter, Jr. et al.	N/A	N/A
6129823	12/1999	Hughes et al.	N/A	N/A
6134461	12/1999	Say et al.	N/A	N/A
6141573	12/1999	Kurnik et al.	N/A	N/A
6143164	12/1999	Heller et al.	N/A	N/A
6159147	12/1999	Lichter et al.	N/A	N/A
6162611	12/1999	Heller et al.	N/A	N/A
6175752	12/2000	Say et al.	N/A	N/A
6200265	12/2000	Walsh et al.	N/A	N/A
6212416	12/2000	Ward et al.	N/A	N/A
6219574	12/2000	Cormier et al.	N/A	N/A
6248067	12/2000	Causey, III et al.	N/A	N/A
6254586	12/2000	Mann et al.	N/A	N/A
6270455	12/2000	Brown	N/A	N/A
6275717	12/2000	Gross et al.	N/A	N/A
6283761	12/2000	Joao	N/A	N/A
6284478	12/2000	Heller et al.	N/A	N/A
6293925	12/2000	Safabash et al.	N/A	N/A
6295506	12/2000	Heinonen et al.	N/A	N/A
6306104	12/2000	Cunningham et al.	N/A	N/A
6309884	12/2000	Cooper et al.	N/A	N/A
6314317	12/2000	Willis	N/A	N/A
6329161	12/2000	Heller et al.	N/A	N/A
6348640	12/2001	Navot et al.	N/A	N/A
6359270	12/2001	Bridson	N/A	N/A
6359444	12/2001	Grimes	N/A	N/A
6360888	12/2001	McIvor et al.	N/A	N/A
6366794	12/2001	Moussy et al.	N/A	N/A
6377828	12/2001	Chaiken et al.	N/A	N/A
6379301	12/2001	Worthington et al.	N/A	N/A
6418332	12/2001	Mastrototaro et al.	N/A	N/A
6424847	12/2001	Mastrototaro et al.	N/A	N/A

6427088	12/2001	Bowman, IV et al.	N/A	N/A
6440068	12/2001	Brown et al.	N/A	N/A
6471689	12/2001	Joseph et al.	N/A	N/A
6478736	12/2001	Mault	N/A	N/A
6484045	12/2001	Holker et al.	N/A	N/A
6484046	12/2001	Say et al.	N/A	N/A
6493069	12/2001	Nagashimada et al.	N/A	N/A
6498043	12/2001	Schulman et al.	N/A	N/A
6514718	12/2002	Heller et al.	N/A	N/A
6546268	12/2002	Ishikawa et al.	N/A	N/A
6551494	12/2002	Heller et al.	N/A	N/A
6554798	12/2002	Mann et al.	N/A	N/A
6558321	12/2002	Burd et al.	N/A	N/A
6558351	12/2002	Steil et al.	N/A	N/A
6560471	12/2002	Heller et al.	N/A	N/A
6561978	12/2002	Conn et al.	N/A	N/A
6562001	12/2002	Lebel et al.	N/A	N/A
6564105	12/2002	Starkweather et al.	N/A	N/A
6565509	12/2002	Say et al.	N/A	N/A
6571128	12/2002	Lebel et al.	N/A	N/A
6572542	12/2002	Houben et al.	N/A	N/A
6574490	12/2002	Abbink et al.	N/A	N/A
6576101	12/2002	Heller et al.	N/A	N/A
6577899	12/2002	Lebel et al.	N/A	N/A
6579690	12/2002	Bonnecaze et al.	N/A	N/A
6585644	12/2002	Lebel et al.	N/A	N/A
6591125	12/2002	Buse et al.	N/A	N/A
6595919	12/2002	Bemer et al.	N/A	N/A
6600997	12/2002	Deweese et al.	N/A	N/A
6605200	12/2002	Mao et al.	N/A	N/A
6605201	12/2002	Mao et al.	N/A	N/A
6607509	12/2002	Bobroff et al.	N/A	N/A
6610012	12/2002	Mault	N/A	N/A
6633772	12/2002	Ford et al.	N/A	N/A
6635014	12/2002	Starkweather et al.	N/A	N/A
6641533	12/2002	Causey, III et al.	N/A	N/A
6648821	12/2002	Lebel et al.	N/A	N/A
6654625	12/2002	Say et al.	N/A	N/A
6658396	12/2002	Tang et al.	N/A	N/A
6659948	12/2002	Lebel et al.	N/A	N/A
6668196	12/2002	Villegas et al.	N/A	N/A
6675030	12/2003	Ciurczak et al.	N/A	N/A
6676816	12/2003	Mao et al.	N/A	N/A
6687546	12/2003	Lebel et al.	N/A	N/A
6689056	12/2003	Kilcoyne et al.	N/A	N/A
6694191	12/2003	Starkweather et al.	N/A	N/A
6695860	12/2003	Ward et al.	N/A	N/A
6702857	12/2003	Brauker et al.	N/A	N/A
6733446	12/2003	Lebel et al.	N/A	N/A
6740075	12/2003	Lebel et al.	N/A	N/A

6741877	12/2003	Shults et al.	N/A	N/A
6743635	12/2003	Neel et al.	N/A	N/A
6746582	12/2003	Heller et al.	N/A	N/A
6749740	12/2003	Liamos et al.	N/A	N/A
6758810	12/2003	Lebel et al.	N/A	N/A
6770030	12/2003	Schaupp et al.	N/A	N/A
6789195	12/2003	Prihoda et al.	N/A	N/A
6790178	12/2003	Mault et al.	N/A	N/A
6809653	12/2003	Mann et al.	N/A	N/A
6810290	12/2003	Lebel et al.	N/A	N/A
6811533	12/2003	Lebel et al.	N/A	N/A
6811534	12/2003	Bowman, IV et al.	N/A	N/A
6813519	12/2003	Lebel et al.	N/A	N/A
6837858	12/2004	Cunningham et al.	N/A	N/A
6862465	12/2004	Shults et al.	N/A	N/A
6873268	12/2004	Lebel et al.	N/A	N/A
6881551	12/2004	Heller et al.	N/A	N/A
6892085	12/2004	McIvor et al.	N/A	N/A
6895265	12/2004	Silver	N/A	N/A
6923763	12/2004	Kovatchev et al.	N/A	N/A
6931327	12/2004	Goode, Jr. et al.	N/A	N/A
6932894	12/2004	Mao et al.	N/A	N/A
6936006	12/2004	Sabra	N/A	N/A
6942518	12/2004	Liamos et al.	N/A	N/A
6950708	12/2004	Bowman, IV et al.	N/A	N/A
6958705	12/2004	Lebel et al.	N/A	N/A
6968294	12/2004	Gutta et al.	N/A	N/A
6971274	12/2004	Olin	N/A	N/A
6974437	12/2004	Lebel et al.	N/A	N/A
6990366	12/2005	Say et al.	N/A	N/A
6997907	12/2005	Safabash et al.	N/A	N/A
6998247	12/2005	Monfre et al.	N/A	N/A
6999854	12/2005	Roth	N/A	N/A
7003336	12/2005	Holker et al.	N/A	N/A
7003340	12/2005	Say et al.	N/A	N/A
7003341	12/2005	Say et al.	N/A	N/A
7015817	12/2005	Copley et al.	N/A	N/A
7016713	12/2005	Gardner et al.	N/A	N/A
7024245	12/2005	Lebel et al.	N/A	N/A
7025774	12/2005	Freeman et al.	N/A	N/A
7027848	12/2005	Robinson et al.	N/A	N/A
7027931	12/2005	Jones et al.	N/A	N/A
7041068	12/2005	Freeman et al.	N/A	N/A
7041468	12/2005	Drucker et al.	N/A	N/A
7046153	12/2005	Oja et al.	N/A	N/A
7052483	12/2005	Woicik	N/A	N/A
7056302	12/2005	Douglas	N/A	N/A
7074307	12/2005	Simpson et al.	N/A	N/A
7081195	12/2005	Simpson et al.	N/A	N/A
7092891	12/2005	Maus et al.	N/A	N/A

7098803	12/2005	Mann et al.	N/A	N/A
7108778	12/2005	Simpson et al.	N/A	N/A
7110803	12/2005	Shults et al.	N/A	N/A
7113821	12/2005	Sun et al.	N/A	N/A
7123950	12/2005	Mannheimer	N/A	N/A
7134999	12/2005	Brauker et al.	N/A	N/A
7136689	12/2005	Shults et al.	N/A	N/A
7153265	12/2005	Vachon	N/A	N/A
7155290	12/2005	Von Arx et al.	N/A	N/A
7171274	12/2006	Starkweather et al.	N/A	N/A
7179226	12/2006	Crothall et al.	N/A	N/A
7190988	12/2006	Say et al.	N/A	N/A
7192450	12/2006	Brauker et al.	N/A	N/A
7198606	12/2006	Boecker et al.	N/A	N/A
7207974	12/2006	Safabash et al.	N/A	N/A
7226442	12/2006	Sheppard et al.	N/A	N/A
7226978	12/2006	Tapsak et al.	N/A	N/A
7276029	12/2006	Goode, Jr. et al.	N/A	N/A
7278983	12/2006	Ireland et al.	N/A	N/A
7286894	12/2006	Grant et al.	N/A	N/A
7299082	12/2006	Feldman et al.	N/A	N/A
7310544	12/2006	Brister et al.	N/A	N/A
7324012	12/2007	Mann et al.	N/A	N/A
7329239	12/2007	Safabash et al.	N/A	N/A
7364592	12/2007	Carr-Brendel et al.	N/A	N/A
7366556	12/2007	Brister et al.	N/A	N/A
7379765	12/2007	Petisce et al.	N/A	N/A
7381184	12/2007	Funderburk et al.	N/A	N/A
7402153	12/2007	Steil et al.	N/A	N/A
7424318	12/2007	Brister et al.	N/A	N/A
7429258	12/2007	Angel et al.	N/A	N/A
7455663	12/2007	Bikovsky	N/A	N/A
7460898	12/2007	Brister et al.	N/A	N/A
7462264	12/2007	Heller et al.	N/A	N/A
7467003	12/2007	Brister et al.	N/A	N/A
7471972	12/2007	Rhodes et al.	N/A	N/A
7494465	12/2008	Brister et al.	N/A	N/A
7497827	12/2008	Brister et al.	N/A	N/A
7499002	12/2008	Blasko et al.	N/A	N/A
7519408	12/2008	Rasdal et al.	N/A	N/A
7583990	12/2008	Goode, Jr. et al.	N/A	N/A
7591801	12/2008	Brauker et al.	N/A	N/A
7599726	12/2008	Goode, Jr. et al.	N/A	N/A
7613491	12/2008	Boock et al.	N/A	N/A
7615007	12/2008	Shults et al.	N/A	N/A
7632228	12/2008	Brauker et al.	N/A	N/A
7635594	12/2008	Holmes et al.	N/A	N/A
7637868	12/2008	Saint et al.	N/A	N/A
7640048	12/2008	Dobbies et al.	N/A	N/A
7651596	12/2009	Petisce et al.	N/A	N/A

7651845	12/2009	Doyle, III et al.	N/A	N/A
7654956	12/2009	Brister et al.	N/A	N/A
7657297	12/2009	Simpson et al.	N/A	N/A
7697967	12/2009	Stafford	N/A	N/A
7699775	12/2009	Desai et al.	N/A	N/A
7711402	12/2009	Shults et al.	N/A	N/A
7713574	12/2009	Brister et al.	N/A	N/A
7715893	12/2009	Kamath et al.	N/A	N/A
7727147	12/2009	Osorio et al.	N/A	N/A
7731657	12/2009	Stafford	N/A	N/A
7736310	12/2009	Taub	N/A	N/A
7736344	12/2009	Moberg et al.	N/A	N/A
7763042	12/2009	Iio et al.	N/A	N/A
7766829	12/2009	Sloan et al.	N/A	N/A
7811231	12/2009	Jin et al.	N/A	N/A
7813809	12/2009	Strother et al.	N/A	N/A
7822454	12/2009	Alden et al.	N/A	N/A
7889069	12/2010	Fifolt et al.	N/A	N/A
7899545	12/2010	John	N/A	N/A
7914460	12/2010	Melker et al.	N/A	N/A
7938797	12/2010	Estes	N/A	N/A
7941200	12/2010	Weinert et al.	N/A	N/A
7946985	12/2010	Mastrototaro et al.	N/A	N/A
7972296	12/2010	Braig et al.	N/A	N/A
7976466	12/2010	Ward et al.	N/A	N/A
7978063	12/2010	Baldus et al.	N/A	N/A
8010174	12/2010	Goode, Jr. et al.	N/A	N/A
8010256	12/2010	Oowada	N/A	N/A
8192394	12/2011	Estes et al.	N/A	N/A
8282549	12/2011	Brauker et al.	N/A	N/A
8597570	12/2012	Terashima et al.	N/A	N/A
8764651	12/2013	Tran	N/A	N/A
8771183	12/2013	Sloan	N/A	N/A
8864651	12/2013	Kuyava et al.	N/A	N/A
9241631	12/2015	Valdes et al.	N/A	N/A
9504471	12/2015	Vaitekunas et al.	N/A	N/A
9577934	12/2016	Gross	N/A	N/A
9808574	12/2016	Yodfat et al.	N/A	N/A
9996668	12/2017	Reihman et al.	N/A	N/A
10085640	12/2017	Mensinger et al.	N/A	N/A
10820842	12/2019	Harper	N/A	N/A
10827954	12/2019	Hoss et al.	N/A	N/A
10874338	12/2019	Stafford	N/A	N/A
10881341	12/2020	Curry et al.	N/A	N/A
10945647	12/2020	Mazza et al.	N/A	N/A
10945649	12/2020	Lee et al.	N/A	N/A
10952653	12/2020	Harper	N/A	N/A
10959654	12/2020	Curry et al.	N/A	N/A
10966644	12/2020	Stafford	N/A	N/A
10973443	12/2020	Funderburk et al.	N/A	N/A

10980461	12/2020	Simpson et al.	N/A	N/A
11000213	12/2020	Kamath et al.	N/A	N/A
11000216	12/2020	Curry et al.	N/A	N/A
11013440	12/2020	Lee et al.	N/A	N/A
11064917	12/2020	Simpson et al.	N/A	N/A
11116431	12/2020	Harper	N/A	N/A
11141084	12/2020	Funderburk et al.	N/A	N/A
11298056	12/2021	Harper	N/A	N/A
2001/0020124	12/2000	Tamada	N/A	N/A
2001/0037060	12/2000	Thompson et al.	N/A	N/A
2001/0037366	12/2000	Webb et al.	N/A	N/A
2001/0047604	12/2000	Valiulis	N/A	N/A
2002/0019022	12/2001	Dunn et al.	N/A	N/A
2002/0054320	12/2001	Ogino	N/A	N/A
2002/0095076	12/2001	Krausman et al.	N/A	N/A
2002/0103499	12/2001	Perez et al.	N/A	N/A
2002/0106709	12/2001	Potts et al.	N/A	N/A
2002/0107557	12/2001	Edell et al.	N/A	N/A
2002/0111832	12/2001	Judge	N/A	N/A
2002/0128594	12/2001	Das et al.	N/A	N/A
2002/0133107	12/2001	Darcey	N/A	N/A
2002/0147135	12/2001	Schnell	N/A	N/A
2002/0161288	12/2001	Shin et al.	N/A	N/A
2002/0188748	12/2001	Blackwell et al.	N/A	N/A
2003/0004403	12/2002	Drinan et al.	N/A	N/A
2003/0005464	12/2002	Gropper et al.	N/A	N/A
2003/0021729	12/2002	Moller et al.	N/A	N/A
2003/0023461	12/2002	Quintanilla et al.	N/A	N/A
2003/0028089	12/2002	Galley et al.	N/A	N/A
2003/0060692	12/2002	Ruchti et al.	N/A	N/A
2003/0060753	12/2002	Starkweather et al.	N/A	N/A
2003/0065536	12/2002	Hansen et al.	N/A	N/A
2003/0114897	12/2002	Von Arx et al.	N/A	N/A
2003/0147515	12/2002	Kai et al.	N/A	N/A
2003/0163351	12/2002	Brown	N/A	N/A
2003/0168338	12/2002	Gao et al.	N/A	N/A
2003/0199790	12/2002	Boecker et al.	N/A	N/A
2003/0208113	12/2002	Mault et al.	N/A	N/A
2003/0212379	12/2002	Bylund et al.	N/A	N/A
2004/0010207	12/2003	Flaherty et al.	N/A	N/A
2004/0015102	12/2003	Cummings et al.	N/A	N/A
2004/0041749	12/2003	Dixon	N/A	N/A
2004/0054263	12/2003	Moerman et al.	N/A	N/A
2004/0060818	12/2003	Feldman et al.	N/A	N/A
2004/0063435	12/2003	Sakamoto et al.	N/A	N/A
2004/0064068	12/2003	DeNuzzio et al.	N/A	N/A
2004/0073266	12/2003	Haefner et al.	N/A	N/A
2004/0078215	12/2003	Dahlin et al.	N/A	N/A
2004/0106858	12/2003	Say et al.	N/A	N/A
2004/0122353	12/2003	Shahmirian et al.	N/A	N/A

2004/0133164	12/2003	Funderburk et al.	N/A	N/A
2004/0133390	12/2003	Osorio et al.	N/A	N/A
2004/0135684	12/2003	Steinthal et al.	N/A	N/A
2004/0138588	12/2003	Saikley et al.	N/A	N/A
2004/0147872	12/2003	Thompson	N/A	N/A
2004/0152622	12/2003	Keith et al.	N/A	N/A
2004/0167801	12/2003	Say et al.	N/A	N/A
2004/0171921	12/2003	Say et al.	N/A	N/A
2004/0176672	12/2003	Silver et al.	N/A	N/A
2004/0186365	12/2003	Jin et al.	N/A	N/A
2004/0193025	12/2003	Steil et al.	N/A	N/A
2004/0204687	12/2003	Mogensen et al.	N/A	N/A
2004/0204868	12/2003	Maynard et al.	N/A	N/A
2004/0223985	12/2003	Dunfiled et al.	N/A	N/A
2004/0247671	12/2003	Prescott et al.	N/A	N/A
2004/0249253	12/2003	Racchini et al.	N/A	N/A
2004/0254433	12/2003	Bandis et al.	N/A	N/A
2004/0254434	12/2003	Goodnow et al.	N/A	N/A
2004/0260478	12/2003	Schwamm	N/A	N/A
2004/0267300	12/2003	Mace	N/A	N/A
2005/0001024	12/2004	Kusaka et al.	N/A	N/A
2005/0003470	12/2004	Nelson et al.	N/A	N/A
2005/0004494	12/2004	Perez et al.	N/A	N/A
2005/0027177	12/2004	Shin et al.	N/A	N/A
2005/0031689	12/2004	Shults et al.	N/A	N/A
2005/0038680	12/2004	McMahon	N/A	N/A
2005/0043598	12/2004	Goode, Jr. et al.	N/A	N/A
2005/0049179	12/2004	Davidson et al.	N/A	N/A
2005/0070774	12/2004	Addison et al.	N/A	N/A
2005/0090607	12/2004	Tapsak et al.	N/A	N/A
2005/0096511	12/2004	Fox et al.	N/A	N/A
2005/0096516	12/2004	Soykan et al.	N/A	N/A
2005/0113886	12/2004	Fischell et al.	N/A	N/A
2005/0114068	12/2004	Chey et al.	N/A	N/A
2005/0116683	12/2004	Cheng et al.	N/A	N/A
2005/0137530	12/2004	Campbell et al.	N/A	N/A
2005/0173245	12/2004	Feldman et al.	N/A	N/A
2005/0176136	12/2004	Burd et al.	N/A	N/A
2005/0182306	12/2004	Sloan	N/A	N/A
2005/0184153	12/2004	Auchinleck	N/A	N/A
2005/0187442	12/2004	Cho et al.	N/A	N/A
2005/0192493	12/2004	Wuori	N/A	N/A
2005/0195930	12/2004	Spital et al.	N/A	N/A
2005/0204134	12/2004	Von Arx et al.	N/A	N/A
2005/0214892	12/2004	Kovatchev et al.	N/A	N/A
2005/0245799	12/2004	Brauker et al.	N/A	N/A
2005/0251033	12/2004	Scarantino et al.	N/A	N/A
2005/0277912	12/2004	John	N/A	N/A
2005/0283209	12/2004	Katoozi et al.	N/A	N/A
2006/0001538	12/2005	Kraft et al.	N/A	N/A

2006/0001551	12/2005	Kraft et al.	N/A	N/A
2006/0010098	12/2005	Goodnow et al.	N/A	N/A
2006/0015020	12/2005	Neale et al.	N/A	N/A
2006/0015024	12/2005	Brister et al.	N/A	N/A
2006/0017923	12/2005	Ruchti et al.	N/A	N/A
2006/0020300	12/2005	Nghiern et al.	N/A	N/A
2006/0031094	12/2005	Cohen et al.	N/A	N/A
2006/0079740	12/2005	Silver et al.	N/A	N/A
2006/0091006	12/2005	Wang et al.	N/A	N/A
2006/0099971	12/2005	Staton et al.	N/A	N/A
2006/0142651	12/2005	Brister et al.	N/A	N/A
2006/0154642	12/2005	Scannell	N/A	N/A
2006/0161225	12/2005	Sormann et al.	N/A	N/A
2006/0166629	12/2005	Reggiardo	N/A	N/A
2006/0173406	12/2005	Haves et al.	N/A	N/A
2006/0189863	12/2005	Peyser et al.	N/A	N/A
2006/0193375	12/2005	Lee et al.	N/A	N/A
2006/0202859	12/2005	Mastrototaro et al.	N/A	N/A
2006/0222566	12/2005	Brauker et al.	N/A	N/A
2006/0224109	12/2005	Steil et al.	N/A	N/A
2006/0224141	12/2005	Rush et al.	N/A	N/A
2006/0226985	12/2005	Goodnow et al.	N/A	N/A
2006/0247508	12/2005	Fennell	N/A	N/A
2006/0247985	12/2005	Liamos et al.	N/A	N/A
2006/0258929	12/2005	Goode et al.	N/A	N/A
2006/0272652	12/2005	Stocker et al.	N/A	N/A
2006/0290496	12/2005	Peeters et al.	N/A	N/A
2006/0293607	12/2005	Alt et al.	N/A	N/A
2007/0010950	12/2006	Abensour et al.	N/A	N/A
2007/0016381	12/2006	Karnath et al.	N/A	N/A
2007/0017983	12/2006	Frank et al.	N/A	N/A
2007/0027381	12/2006	Stafford	N/A	N/A
2007/0033074	12/2006	Nitzan et al.	N/A	N/A
2007/0060869	12/2006	Tolle et al.	N/A	N/A
2007/0060979	12/2006	Strother et al.	N/A	N/A
2007/0066956	12/2006	Finkel	N/A	N/A
2007/0073129	12/2006	Shah et al.	N/A	N/A
2007/0078320	12/2006	Stafford	N/A	N/A
2007/0078321	12/2006	Mazza et al.	N/A	N/A
2007/0078322	12/2006	Stafford	N/A	N/A
2007/0078818	12/2006	Zvitz et al.	N/A	N/A
2007/0093786	12/2006	Goldsmith et al.	N/A	N/A
2007/0118030	12/2006	Bruce et al.	N/A	N/A
2007/0149875	12/2006	Ouyang et al.	N/A	N/A
2007/0173706	12/2006	Neinast et al.	N/A	N/A
2007/0173708	12/2006	Dobbies et al.	N/A	N/A
2007/0173709	12/2006	Petisce et al.	N/A	N/A
2007/0173710	12/2006	Petisce et al.	N/A	N/A
2007/0191702	12/2006	Yodfat et al.	N/A	N/A
2007/0203407	12/2006	Hoss et al.	N/A	N/A

2007/0203539	12/2006	Stone et al.	N/A	N/A
2007/0203966	12/2006	Brauker et al.	N/A	N/A
2007/0208246	12/2006	Brauker et al.	N/A	N/A
2007/0228071	12/2006	Kamen et al.	N/A	N/A
2007/0231846	12/2006	Cosentino et al.	N/A	N/A
2007/0232878	12/2006	Kovatchev et al.	N/A	N/A
2007/0235331	12/2006	Simpson et al.	N/A	N/A
2007/0249922	12/2006	Peyser et al.	N/A	N/A
2007/0255116	12/2006	Mehta et al.	N/A	N/A
2007/0255321	12/2006	Gerber et al.	N/A	N/A
2007/0255348	12/2006	Holtzclaw	N/A	N/A
2008/0004904	12/2007	Tran	N/A	N/A
2008/0009692	12/2007	Stafford	N/A	N/A
2008/0033254	12/2007	Karnath et al.	N/A	N/A
2008/0039702	12/2007	Hayter et al.	N/A	N/A
2008/0045824	12/2007	Tapsak et al.	N/A	N/A
2008/0060955	12/2007	Goodnow	N/A	N/A
2008/0061961	12/2007	John	N/A	N/A
2008/0081977	12/2007	Hayter et al.	N/A	N/A
2008/0083617	12/2007	Simpson et al.	N/A	N/A
2008/0092638	12/2007	Brenneman et al.	N/A	N/A
2008/0114228	12/2007	McCluskey et al.	N/A	N/A
2008/0119705	12/2007	Patel et al.	N/A	N/A
2008/0125636	12/2007	Ward et al.	N/A	N/A
2008/0127052	12/2007	Stoker	N/A	N/A
2008/0161666	12/2007	Feldman et al.	N/A	N/A
2008/0172205	12/2007	Breton et al.	N/A	N/A
2008/0177149	12/2007	Weinert et al.	N/A	N/A
2008/0194934	12/2007	Ray et al.	N/A	N/A
2008/0194938	12/2007	Brister et al.	N/A	N/A
2008/0197024	12/2007	Simpson et al.	N/A	N/A
2008/0200788	12/2007	Brister et al.	N/A	N/A
2008/0200789	12/2007	Brister et al.	N/A	N/A
2008/0200791	12/2007	Simpson et al.	N/A	N/A
2008/0201325	12/2007	Doniger et al.	N/A	N/A
2008/0208025	12/2007	Shults et al.	N/A	N/A
2008/0214900	12/2007	Fennell et al.	N/A	N/A
2008/0214918	12/2007	Brister et al.	N/A	N/A
2008/0228045	12/2007	Gao et al.	N/A	N/A
2008/0228051	12/2007	Shults et al.	N/A	N/A
2008/0228054	12/2007	Shults et al.	N/A	N/A
2008/0228055	12/2007	Sher	N/A	N/A
2008/0234943	12/2007	Ray et al.	N/A	N/A
2008/0242961	12/2007	Brister et al.	N/A	N/A
2008/0242963	12/2007	Essenpreis et al.	N/A	N/A
2008/0254544	12/2007	Modzelewski et al.	N/A	N/A
2008/0262469	12/2007	Brister et al.	N/A	N/A
2008/0269714	12/2007	Mastrototaro et al.	N/A	N/A
2008/0269723	12/2007	Mastrototaro et al.	N/A	N/A
2008/0287764	12/2007	Rasdal et al.	N/A	N/A

2008/0296155	12/2007	Shults et al.	N/A	N/A
2008/0300572	12/2007	Rankers et al.	N/A	N/A
2008/0306434	12/2007	Dobbies et al.	N/A	N/A
2008/0306435	12/2007	Karnath et al.	N/A	N/A
2008/0306444	12/2007	Brister et al.	N/A	N/A
2008/0312841	12/2007	Hayter	N/A	N/A
2008/0312859	12/2007	Skyggebjerg et al.	N/A	N/A
2008/0319085	12/2007	Wright et al.	N/A	N/A
2009/0006061	12/2008	Thukral et al.	N/A	N/A
2009/0012377	12/2008	Jennewine et al.	N/A	N/A
2009/0018424	12/2008	Karnath et al.	N/A	N/A
2009/0024177	12/2008	Shuros et al.	N/A	N/A
2009/0030294	12/2008	Petisce et al.	N/A	N/A
2009/0033482	12/2008	Hayter et al.	N/A	N/A
2009/0036758	12/2008	Brauker et al.	N/A	N/A
2009/0036763	12/2008	Brauker et al.	N/A	N/A
2009/0040022	12/2008	Finkenzeller	N/A	N/A
2009/0043181	12/2008	Brauker et al.	N/A	N/A
2009/0048503	12/2008	Dalal et al.	N/A	N/A
2009/0054747	12/2008	Fennell	N/A	N/A
2009/0054748	12/2008	Feldman	N/A	N/A
2009/0054749	12/2008	He	N/A	N/A
2009/0055149	12/2008	Hayter et al.	N/A	N/A
2009/0062633	12/2008	Brauker et al.	N/A	N/A
2009/0076356	12/2008	Simpson et al.	N/A	N/A
2009/0076360	12/2008	Brister et al.	N/A	N/A
2009/0082693	12/2008	Stafford	N/A	N/A
2009/0085768	12/2008	Patel et al.	N/A	N/A
2009/0085873	12/2008	Betts et al.	N/A	N/A
2009/0088787	12/2008	Koike et al.	N/A	N/A
2009/0093687	12/2008	Telfort et al.	N/A	N/A
2009/0099436	12/2008	Brister et al.	N/A	N/A
2009/0105636	12/2008	Hayter et al.	N/A	N/A
2009/0124879	12/2008	Brister et al.	N/A	N/A
2009/0124964	12/2008	Leach et al.	N/A	N/A
2009/0131768	12/2008	Simpson et al.	N/A	N/A
2009/0131769	12/2008	Leach et al.	N/A	N/A
2009/0131776	12/2008	Simpson et al.	N/A	N/A
2009/0131777	12/2008	Simpson et al.	N/A	N/A
2009/0131860	12/2008	Nielsen	N/A	N/A
2009/0137886	12/2008	Shariati et al.	N/A	N/A
2009/0137887	12/2008	Shariati et al.	N/A	N/A
2009/0143659	12/2008	Li et al.	N/A	N/A
2009/0156924	12/2008	Shariati et al.	N/A	N/A
2009/0163791	12/2008	Brister et al.	N/A	N/A
2009/0178459	12/2008	Li et al.	N/A	N/A
2009/0182217	12/2008	Li et al.	N/A	N/A
2009/0192366	12/2008	Mensinger et al.	N/A	N/A
2009/0192380	12/2008	Shariati et al.	N/A	N/A
2009/0192722	12/2008	Shariati et al.	N/A	N/A

2009/0192724	12/2008	Brauker et al.	N/A	N/A
2009/0192745	12/2008	Karnath et al.	N/A	N/A
2009/0192751	12/2008	Karnath et al.	N/A	N/A
2009/0198118	12/2008	Hayter et al.	N/A	N/A
2009/0216100	12/2008	Ebner et al.	N/A	N/A
2009/0216103	12/2008	Brister et al.	N/A	N/A
2009/0240120	12/2008	Mensinger et al.	N/A	N/A
2009/0240128	12/2008	Mensinger et al.	N/A	N/A
2009/0240193	12/2008	Mensinger et al.	N/A	N/A
2009/0242399	12/2008	Karnath et al.	N/A	N/A
2009/0242425	12/2008	Karnath et al.	N/A	N/A
2009/0247855	12/2008	Boock et al.	N/A	N/A
2009/0247856	12/2008	Boock et al.	N/A	N/A
2009/0247857	12/2008	Harper et al.	N/A	N/A
2009/0298182	12/2008	Schulat et al.	N/A	N/A
2009/0299155	12/2008	Yang et al.	N/A	N/A
2009/0299156	12/2008	Simpson et al.	N/A	N/A
2009/0299162	12/2008	Brauker et al.	N/A	N/A
2009/0299276	12/2008	Brauker et al.	N/A	N/A
2010/0076283	12/2009	Simpson et al.	N/A	N/A
2010/0093786	12/2009	Watanabe et al.	N/A	N/A
2010/0096259	12/2009	Zhang et al.	N/A	N/A
2010/0105999	12/2009	Dixon et al.	N/A	N/A
2010/0113897	12/2009	Brenneman et al.	N/A	N/A
2010/0141656	12/2009	Krieftewirth	N/A	N/A
2010/0145377	12/2009	Lai et al.	N/A	N/A
2010/0146300	12/2009	Brown	N/A	N/A
2010/0152554	12/2009	Steine et al.	N/A	N/A
2010/0160759	12/2009	Celentano et al.	N/A	N/A
2010/0168538	12/2009	Keenan et al.	N/A	N/A
2010/0168540	12/2009	Karnath et al.	N/A	N/A
2010/0168541	12/2009	Karnath et al.	N/A	N/A
2010/0168542	12/2009	Karnath et al.	N/A	N/A
2010/0168543	12/2009	Karnath et al.	N/A	N/A
2010/0168544	12/2009	Karnath et al.	N/A	N/A
2010/0168545	12/2009	Karnath et al.	N/A	N/A
2010/0168546	12/2009	Karnath et al.	N/A	N/A
2010/0168657	12/2009	Karnath et al.	N/A	N/A
2010/0174168	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0174266	12/2009	Estes	N/A	N/A
2010/0179399	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0179402	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0179405	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0179408	12/2009	Karnath et al.	N/A	N/A
2010/0179409	12/2009	Karnath et al.	N/A	N/A
2010/0185065	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0185071	12/2009	Simpson et al.	N/A	N/A
2010/0185072	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0185073	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0185074	12/2009	Goode, Jr. et al.	N/A	N/A

2010/0185075	12/2009	Brister et al.	N/A	N/A
2010/0185175	12/2009	Kamen et al.	N/A	N/A
2010/0198034	12/2009	Thomas et al.	N/A	N/A
2010/0198035	12/2009	Karnath et al.	N/A	N/A
2010/0198142	12/2009	Sloan et al.	N/A	N/A
2010/0213057	12/2009	Feldman et al.	N/A	N/A
2010/0213080	12/2009	Celentano et al.	N/A	N/A
2010/0217105	12/2009	Yodfat et al.	N/A	N/A
2010/0262201	12/2009	He et al.	N/A	N/A
2010/0313105	12/2009	Nekoomaram et al.	N/A	N/A
2010/0331642	12/2009	Bruce et al.	N/A	N/A
2011/0002223	12/2010	Gross	N/A	N/A
2011/0024043	12/2010	Boock et al.	N/A	N/A
2011/0024307	12/2010	Simpson et al.	N/A	N/A
2011/0027127	12/2010	Simpson et al.	N/A	N/A
2011/0027453	12/2010	Boock et al.	N/A	N/A
2011/0027458	12/2010	Boock et al.	N/A	N/A
2011/0028815	12/2010	Simpson et al.	N/A	N/A
2011/0028816	12/2010	Simpson et al.	N/A	N/A
2011/0031986	12/2010	Bhat et al.	N/A	N/A
2011/0077490	12/2010	Simpson et al.	N/A	N/A
2011/0148905	12/2010	Simmons et al.	N/A	N/A
2011/0178461	12/2010	Chong et al.	N/A	N/A
2011/0208027	12/2010	Wagner et al.	N/A	N/A
2011/0257895	12/2010	Brauker et al.	N/A	N/A
2011/0287528	12/2010	Fern et al.	N/A	N/A
2011/0320130	12/2010	Valdes et al.	N/A	N/A
2012/0078071	12/2011	Bohm et al.	N/A	N/A
2012/0108931	12/2011	Taub et al.	N/A	N/A
2012/0108934	12/2011	Valdes et al.	N/A	N/A
2012/0165626	12/2011	Irina et al.	N/A	N/A
2012/0165640	12/2011	Galley et al.	N/A	N/A
2013/0035575	12/2012	Mayou et al.	N/A	N/A
2013/0127627	12/2012	Hayter et al.	N/A	N/A
2013/0235166	12/2012	Jones et al.	N/A	N/A
2014/0176338	12/2013	He et al.	N/A	N/A
2017/0112531	12/2016	Schoonmaker et al.	N/A	N/A
2019/0216373	12/2018	Harper	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	**Application Date**	**Country**	**CPC**
0098592	12/1983	EP	N/A
0127958	12/1983	EP	N/A
0320109	12/1988	EP	N/A
0390390	12/1989	EP	N/A
0396788	12/1989	EP	N/A
1 707 115	12/2005	EP	N/A
WO-00/59370	12/1999	WO	N/A
WO 00/62664	12/1999	WO	N/A
WO-01/52935	12/2000	WO	N/A

WO-01/54753	12/2000	WO	N/A
WO-03/82091	12/2002	WO	N/A
WO-2008/001366	12/2007	WO	N/A
WO 2008/051409	12/2007	WO	N/A
WO 2008/052199	12/2007	WO	N/A
WO 2008/061552	12/2007	WO	N/A
WO 2009/005952	12/2008	WO	N/A

OTHER PUBLICATIONS

Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526. cited by applicant

Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics. vol. 4, No. 1, 2002, pp. 25-33. cited by applicant

Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10. cited by applicant

Brooks, S. L., et al., “Development of an On-line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987, pp. 45-56. cited by applicant

Cass, A. E.G., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56, No. 4, 1984, pp. 667-671. cited by applicant

Cheyne, E.H., et al., “Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers”, Diabetes Technology & Therapeutics, vol. 4, No. 5, 2002, pp. 607-613. cited by applicant

Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on “Wired” Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244. cited by applicant

Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5 No. 5, 2003, pp. 769-779. cited by applicant

Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004. cited by applicant

Isermann, R., “Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639-652. cited by applicant

Isermann, R., et al., “Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709-719. cited by applicant

Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, p. 198. cited by applicant

Jovanovic, L., “The Role of Continuous Glucose Monitoring in Gestational Diabetes Mellitus”, Diabetes Technology & Therapeutics, vol. 2, Suppl. 1, 2000, pp. S67-S71. cited by applicant

Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients With Type 1 Diabetes?”, Diabetologia, vol. 45, 2002, pp. 250. cited by applicant

Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304. cited by applicant

Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549. cited by applicant

Lodwig, V., et al., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 573-587. cited by applicant

Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short-Range Connectivity

Technology", Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74. cited by applicant
Malin, S. F., et al., "Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy", Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658. cited by applicant
McGarraugh, G., et al., "Glucose Measurements Using Blood Extracted from the Forearm and the Finger", TheraSense, Inc., 2001, 16 Pages. cited by applicant
McGarraugh, G., et al., "Physiological Influences on Off-Finger Glucose Testing", Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376. cited by applicant
McKean, B. D., et al., "A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors", IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532. cited by applicant
Morbiducci, U., et al., "Improved usability of the minimal model of insulin sensitivity based on an automated approach and genetic algorithms for parameter estimation", Clinical Science, vol. 112, 2007, pp. 257-263. cited by applicant
Mougiakakou, S.G., et al., "A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients", Proceedings of the 2005 IEEE Engineering in Medicine and Biology 27.SUP.th .Annual Conference, 2005, pp. 298-301. cited by applicant
Parker, R., et al., "Robust H.SUB.∞ .Glucose Control in Diabetes Using a Physiological Model", AIChE Journal, vol. 46, No. 12, 2000, pp. 2537-2549. cited by applicant
Pickup, J. C., et al., "Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy", Biosensors, vol. 3, 1987/88, pp. 335-346. cited by applicant
Pickup, J. C., et al., "In vivo molecular sensing in diabetes mellitus: an implantable glucose sensor with direct electron transfer", Diabetologia, vol. 32, 1989, pp. 213-217. cited by applicant
Pishko, M. V., et al., "Amperometric Glucose Microelectrodes Prepared t hrough Immobilization of Glucose Oxidase in Redox Hydrogels", Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272. cited by applicant
Quinn, C. P., et al., "Kinetics of glucose delivery to subcutaneous tissue in rats measured with 0.3-mm amperometric microsensors", American Journal of Physiology, vol. 269, No. 1, 1995, E155-E161. cited by applicant
Roe, J. N., et al., "Bloodless Glucose Measurements", Critical Reviews™ in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241. cited by applicant
Sakakida, M., et al., "Development of ferrocene-mediated needle-type glucose sensor as a measure of true subcutaneous tissue glucose concentrations", Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158. cited by applicant
Sakakida, M., et al., "Ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane", Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322. cited by applicant
Salehi, C., et al., "A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors", Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308. cited by applicant
Schmidtke, D. W., et al., "Measurement and modeling of the transient difference between blood and subcutaneous glucose concentrations in the rat after injection of insulin", Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299. cited by applicant
Shaw, G. W., et al., "In Vitro testing of a simply constructed, highly s table glucose s ensor suitable for i mplantation in d iabetic p atients", Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406. cited by applicant
Shichiri, M., et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas", Diabetologia, vol. 24, 1983, pp. 179-184. cited by applicant
Shichiri, M., et al., "In Vivo Characteristics of Needle-Type Glucose Sensor-Measurements of Subcutaneous Glucose Concentrations in Human Volunteers", Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20. cited by applicant

Shichiri, M., et al., “Membrane design for extending the l ong-life of an implantable g lucose sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313. cited by applicant
Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210. cited by applicant
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301. cited by applicant
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor”, The Lancet, 1982, pp. 1129-1131. cited by applicant
Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942. cited by applicant
Sternberg, R., et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40. cited by applicant
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261. cited by applicant
Turner, A.P.F., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115. cited by applicant
Updike, S. J., et al., “Principles of Long-term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from i nside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous In vivo Monitoring, Chapter 4, 1997, pp. 117-137. cited by applicant
Velho, G., et al., “Strategies for calibrating a subcutaneous glucose sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964. cited by applicant
Wilson, G. S., et al., “Progress toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617. cited by applicant
US, Exhibit 653-1 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 653-2 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 653-3 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 653-4 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 653-5 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-1 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-2 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-3 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-4 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-5 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Defendant Dexcom, Inc.'s Corrected First Supplemental Response to Plaintiffs' Interrogatories 3 and 4, Case 21-CV-977-KAJ (D. Delaware), Mar. 31, 2022. cited by applicant
US, Dexcom, Inc.'s Answer to First Amended Complaint and Affirmative Defenses to Plaintiffs'

First Amended Complaint, Case 21-CV-977-KAJ (D. Delaware), Feb. 22, 2022. cited by applicant
US, Transcript of Oral Arguments, Case 21-CV-977-KAJ (D. Delaware), Feb. 11, 2022. cited by applicant
US, Order Denying Dexcom, Inc.'s Motion to Dismiss, Case 21-CV-977-KAJ (D. Delaware), Feb. 8, 2022. cited by applicant
US, Defendant Dexcom, Inc.'s Response to Plaintiffs First Set of Interrogatories, Case 21-CV-977-KAJ (D. Delaware), Dec. 10, 2021. cited by applicant
US, Defendant Dexcom, Inc.'s Reply Brief in Support of its Motion to Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(6), Case 21-CV-977-KAJ (D. Delaware), Nov. 22, 2021. cited by applicant
US, Plaintiffs Answering Brief in Opposition to Defendant Motion to Dismiss Under Rule 12(b)(6), Case 21-CV-977-KAJ (D. Delaware), Nov. 15, 2021. cited by applicant
US, Defendant Dexcom, Inc.'s Appendix to Opening Brief in Support of its Motion to Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(6), Case 21-CV-977-KAJ (D. Delaware), Nov. 1, 2021. cited by applicant
US, Defendant Dexcom, Inc.'s Opening Brief in Support of its Motion to Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(6), Case 21-CV-977-KAJ (D. Delaware), Nov. 1, 2021. cited by applicant
US, Defendant Dexcom, Inc.'s Motion to Dismiss Under Rule 12(b)(6), Case 21-CV-977-KAJ (D. Delaware), Nov. 1, 2021. cited by applicant
US, First Amended Complaint filed by Abbott Diabetes Care Inc. and Abbott Diabetes Care Limited against Dexcom, Inc., Case 21-CV-977-KAJ (D. Delaware), Oct. 4, 2021. cited by applicant
US, Complaint filed by Abbott Diabetes Care Inc. and Abbott Diabetes Care Limited against Dexcom, Inc., Case 21-CV-977-KAJ (D. Delaware), Jul. 1, 2021. cited by applicant
Graff, T., et al., “Ocean Systems Test and Evaluation Program—Data Communications Plan”, National Oceanic and Atmospheric Administration, 2006, pp. 1-199. cited by applicant
Guardian® RT Continuous Glucose Monitoring System REF MMT-7900 User Guide, 2005, pp. 1-128. cited by applicant
Medtronic Guardian® REAL-Time Continuous Glucose Monitoring System User Guide, 2006, pp. 1-181. cited by applicant
US, Exhibit 653-1S from DexCom, Inc.'s First Supplemental Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 653-4S from DexCom, Inc.'s First Supplemental Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 653-5S from DexCom, Inc.'s First Supplemental Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 653-6 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-1S from DexCom, Inc.'s First Supplemental Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-4S from DexCom, Inc.'s First Supplemental Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-5S from DexCom, Inc.'s First Supplemental Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Exhibit 842-6 from DexCom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Defendant Dexcom, Inc.'s First Supplemental Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), May 6, 2022. cited by applicant
US, Defendant Dexcom, Inc.'s Preliminary Invalidity Contentions, Case No. 21-CV-977-KAJ (D.

Delaware), May 6, 2022. cited by applicant
Exhibit 842-6F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 842-5F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 842-3F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 842-2F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 842-1F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 653-6F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 653-5F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 653-3F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 653-2F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Exhibit 653-1F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2023. cited by applicant
Defendant Dexcom, Inc's Objections and Responses to Plaintiffs' Second Set of Interrogatories, Case 21-CV-977-KAJ (D. Delaware), Oct. 11, 2022. cited by applicant
Defendant Dexcom, Inc's Second Supplemental Preliminary Invalidity Contentions, Oct. 4, 2022. cited by applicant
Defendant's Comments on Plaintiffs' Technology Tutorial, Case 21-CV-977-KAJ (D. Delaware)—Redacted Version, Sep. 16, 2022. cited by applicant
Plaintiffs' Response to Defendant's Third Set of Interrogatories, Nos. 12-15, Case 21-CV-977-KAJ (D. Delaware), Sep. 14, 2022. cited by applicant
Plaintiffs' Comments on Defendant's Technology Tutorial, Case 21-CV-977-KAJ (D. Delaware), Sep. 9, 2022. cited by applicant
Plaintiffs' Second Supplemental Response to Defendant's First Set of Interrogatories, Nos. 1-10, Interrogatory No. 5, Case 21-CV-977-KAJ (D. Delaware), Sep. 8, 2022. cited by applicant
Plaintiffs' First Updated Identification of Asserted Claims, Case 21-CV-977-KAJ (D. Delaware), Sep. 7, 2022. cited by applicant
Second Declaration of John D. Villasenor, PH.D, Case 21-CV-977-KAJ (D. Delaware), Aug. 31, 2022. cited by applicant
Defendant's Sur-Reply Claim Construction Brief, Case 21-CV-977-KAJ (D. Delaware), Aug. 31, 2022. cited by applicant
Expert Declaration of Majid Sarrafzadeh, Ph.D., in Support of Abbott's Reply Claim Construction Brief, Case 21-CV-977-KAJ (D. Delaware), Aug. 17, 2022. cited by applicant
Plaintiffs' Reply Brief Regarding Claim Construction, Case 21-CV-977-KAJ (D. Delaware), Aug. 17, 2022. cited by applicant
Plaintiff's Response to Defendant's Second Set of Interrogatories, No. 11, Case 21-CV-977-KAJ (D. Delaware) of John D. Villasenor, PH.D, Case 21-CV-977-KAJ (D. Delaware), Aug. 8, 2022. cited by applicant
Declaration of John D. Villasenor, PH.D, Case 21-CV-977-KAJ (D. Delaware), Aug. 3, 2022. cited by applicant
Defendant's Answering Claim Construction Brief, Case 21-CV-977-KAJ (D. Delaware), Aug. 3, 2022. cited by applicant

Expert Declaration of Majid Sarrafzadeh, Ph.D., in Support of Abbott's Opening Claim Construction Brief, Case 21-CV-977-KAJ (D. Delaware), Jul. 13, 2022. cited by applicant
Plaintiffs' Opening Claim Construction Brief, Case 21-CV-977-KAJ (D. Delaware), Jul. 13, 2022. cited by applicant
Dexcom, Inc.'s Answer to Second Amended Complaint, Case 21-CV-977-KAJ (D. Delaware), Jun. 30, 2022. cited by applicant
Joint Claim Construction Chart, Case 21-CV-977-KAJ (D. Delaware), Jun. 22, 2022. cited by applicant
Plaintiffs' Second Amended Complaint, Case 21-CV-977-KAJ (D. Delaware), May 20, 2022. cited by applicant
Defendant Dexcom, Inc.'s Supplemental Response to Plaintiff's First Set of Interrogatories, No. 4, Case 21-CV-977-KAJ (D. Delaware), May 9, 2022. cited by applicant
Dexcom, Inc.'s Amended Answer to Second Amended Complaint, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Mar. 17, 2023. cited by applicant
Complaint, Case No. 23-CV-239-UNA (D. Delaware), Mar. 3, 2023. cited by applicant
Exhibit 842-7F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 3, 2023. cited by applicant
Exhibit 842-4F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 3, 2023. cited by applicant
Exhibit 653-4F from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 3, 2023. cited by applicant
Defendant Dexcom, Inc's Supplemental Objections and Responses to Plaintiffs' Second Set of Interrogatories, Nos. 11, 14, 15, 21-25 [Corrected], Case 21-CV-977-KAJ (D. Delaware), Dec. 20, 2022. cited by applicant
“Abbott Receives CE Mark for Freestyle® Libre, A Revolutionary Glucose Monitoring System for People With Diabetes”, 2014, 7 pages. cited by applicant
“Alcove”, Webster's New College Dictionary, 2001, p. 26. cited by applicant
Armstrong, S., “Wireless connectivity for health and sports monitoring: a review”, Br J Sports Med, 2007, vol. 41, pp. 285-289. cited by applicant
Boise, M., “Dexcom CEO Kevin Sayer Explains G6”, 2018, retrieved from https://beyondtype1.org/dexcom-ceo-kevin-sayer-explains-g6/, 9 pages. cited by applicant
Breton, M, D., et al., “Optimum Subcutaneous Glucose Sampling and Fourier Analysis of Continuous Glucose Monitors”, Journal of Diabetes Science and Technology, 2008, vol. 2, No. 3, pp. 495-500. cited by applicant
Buckingham, B., et al., “Real-time continuous glucose monitoring”, Curr Opin Endocrinol Diabetes Obes, 2007, vol. 14, pp. 288-295. cited by applicant
Buckingham, B., “Clinical Overview of Continuous Glucose Monitoring”, Journal of Diabetes Science and Technology, 2008, vol. 2, No. 2, pp. 300-306. cited by applicant
Burge, M.R., et al., “Continuous Glucose Monitoring: The Future of Diabetes Management”, Diabetes Spectrum, 2008, vol. 21, No. 2, pp. 112-119. cited by applicant
Certified True Copy of Preliminary Amendment filed on Apr. 20, 2018 for U.S. Pat. No. 10,827,954, 7 pages. cited by applicant
CGMs Changing Diabetes Management: Kevin Sayer, DIC Interview Transcript, 2019, retrieved from https://www.diabetesincontrol.com/cgms-changing-diabetes-management- kevin-sayer-dic-interview-transcript/, 10 pages. cited by applicant
Choleau, C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-Point Calibration Method”, Biosensor & Bioelectronics, 2002, vol. 17, No. 8, pp. 647-654. cited by applicant
“Deciding When to Submit a 510(k) for a Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff”, 2017, pp. 1-77. cited by applicant

"Deciding When to Submit a 510(k) for a Software Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff", 2017, pp. 1-31. cited by applicant
Dexcom CEO- Prime Position in Our Market—Mad Money—CNBC.mp4, Transcript 2023 by Sonix, 2 pages. cited by applicant
DexCom (DXCM) 2017 Q4 Earnings Call Transcript, 2017, retrieved from https://docoh.com/transcript/1093557/2017Q4/DXCM, 11 pages. cited by applicant
DexCom (DCXM) Q1 2018 Results - Earnings Call Transcript, 2018, retrieved from https://seekingalpha.com/article/4168949-dexcom-dxcm-q1-2018-results-earnings-call- transcript, 4 pages. cited by applicant
Dexcom, Inc. NasdaqGS:DXCM Company Conference Presentation, 2019, 10 pages. cited by applicant
Dexcom, Inc. NasdaqGS:DXCM Company Conference Presentation, 2020, 9 pages. cited by applicant
Dexcom, Inc. NasdaqGS:DXCM Company Conference Presentation, 2021, 16 pages. cited by applicant
Dexcom G6 Continuous Glucose Monitoring System User Guide, 2019, pp. 1-27. cited by applicant
Dexcom G6 Start Here Set up Guide, 2019, pp. 1-8. cited by applicant
Dexcom G6 Using Your G6 Guide, Mar. 2020, pp. 1-7. cited by applicant
"Does Dexcom Really Have a Future If It Can't Match Abbott's Scale", 2019, retrieved from https://www.sprucepointcap.com/reports/dxcm_research_thesis_3-21-2019.pdf, p. 46. cited by applicant
Email chain from Sophie Hood, oldest email dated Jan. 24, 2023, 5 pages. cited by applicant
"FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices", FDA News Release, 2018, retrieved from https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review, 3 pages. cited by applicant
Frequently Asked Questions About the MiniMed Paradigm® REAL-Time System, 2007, 12 pages. cited by applicant
FreeStyle Navigator Continuous Glucose Monitoring System FDA Premarket Approval (PMA), 2008, pp. 1-7. cited by applicant
Heller, A., et al., "Electrochemical Glucose Sensors and Their Applications in Diabetes Management", Chemical Reviews, 2008, vol. 108, No. 7, pp. 2482-2505. cited by applicant
Hoss, U., et al., "Continuous Glucose Monitoring in Subcutaneous Tissue Using Factory-Calibrated Sensors: A Pilot Study", Diabetes Technology & Therapeutics, 2010, vol. 12, No. 8, pp. 591-597. cited by applicant
Hoss, U., et al., "Feasibility of Factory Calibration for Subcutaneous Glucose Sensors in Subjects With Diabetes", Journal of Diabetes Science and Technology, 2014, vol. 8, No. 1, pp. 89-94. cited by applicant
"Housing", "recess", "release", and "retain", Merriam-Webster's Collegiate Dictionary, Tenth Edition, 1999, pp. 563, 975, 987, and 999. cited by applicant
"Housing" and "recess", The New Penguin English Dictionary, 2000, pp. 678 and 1167. cited by applicant
IEEE 100 The Authoritative Dictionary of IEEE Standards Terms, Seventh Edition, 2000, 3 pages. cited by applicant
"An Interview with Kevin Sayer, President and CEO of Dexcom, About The New G6", 2021, 5 pages. cited by applicant
Keenan, D. B., et al., "Delays in Minimally Invasive Continuous Glucose Monitoring Devices: A Review of Current Technology", Journal of Diabetes Science and Technology, 2009, vol. 3, No. 5, pp. 1207-1214. cited by applicant

Mastrototaro, J. J., “The MiniMed Continuous Glucose Monitoring System”, Diabetes Technology & Therapeutics, 2000, vol. 2, Suppl. 1, pp. S13 - S-18. cited by applicant
Mcgarraugh, G., “The Chemistry of Commercial Continuous Glucose Monitors”, Diabetes Technology & Therapeutics, 2009, vol. 11, Suppl. 1, pp. S17 - S-24. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System, 2007, 6 pages. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time 522 and 722 Sensor Features User Guide, 2006, pp. 1-68. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time System Features, 2007, 6 pages. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time System Frequently Asked Questions, 2007, 6 pages. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time System Fact Sheet, 2007, 6 pages. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time System Premarket Approval (PMA), 2006, pp. 1-3. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time System User Guides, 2007, 2 pages. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time 522 and 722 Insulin Pumps User Guide, 2008, pp. 1-262. cited by applicant
“Medtronic Receives FDA Approval for World's First Insulin Pump with Real-Time Continuous Glucose Monitoring”, News Release, 2006, 2 pages. cited by applicant
Omnipod image, Exhibit 182 of ADC Reply Brief SJ, Daubert, Sep. 22, 2022, 2 pages. cited by applicant
Order, Federal Communications Commission, 2006, pp. 1-8. cited by applicant
Pantelopoulos, A., et al., “A Survey on Wearable Biosensor Systems for Health Monitoring”, 30th Annual International IEEE Embs Conference, 2008, British Columbia, Canada, pp. 4887-4890. cited by applicant
Poitout, V., et al., “A Glucose Monitoring System for On Line Estimation in Man of Blood Glucose Concentration Using a Miniaturized Glucose Sensor Implanted in the Subcutaneous Tissue and a Wearable Control Unit”, Diabetologia, 1993, vol. 36, pp. 658-663. cited by applicant
Program, 2nd International Conference on Advanced Technologies & Treatments for Diabetes, Athens, Greece, 2009, 3 pages. cited by applicant
“Recess”, Cambridge Dictionary of American English, 2000, pp. 710-711. cited by applicant
“Retract”, The Chambers Dictionary, 1998, p. 1410. cited by applicant
“Retract”, The New Oxford American Dictionary, 2001, p. 1455. cited by applicant
“Retract”, Webster's Third New International Dictionary, 1993, pp. 1939-1940. cited by applicant
Roberts, S. S., Mail Call and “The Diabetes Advisor”, Diabetes Forecast, 2007, vol. 60, No. 12, pp. 10, 13, 15, 94, 96, 98, and 100. cited by applicant
Ruder, K., “Continuous Glucose Monitors For Kids”, Diabetes Forecast, 2007, 1 page. cited by applicant
Shenoi, B, A., Introduction to Digital Signal Processing and Filter Design, 2006, Chapter 1, Introduction, pp. 1-31. cited by applicant
Smith, S. W., The Scientist and Engineer's Guide to Digital Signal Processing, Second Edition, 1997-1999, Chapter 28, Digital Signal Processors, pp. 503-534. cited by applicant
Tegnestedt, C., et al., “Levels and sources of sound in the intensive care unit—an observational study of three room types”, Acta Anaesthiesiologica Scandinavica, 2013, pp. 1-10. cited by applicant
Velho, G., et al., “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics”, Diab. Nutr. Metab., 1988, vol. 3, pp. 227-233. cited by applicant
Watkin, J., “An Introduction to Flash Glucose Monitoring”, 14 pages. cited by applicant
14708172.3 Communication of the Board of Appeal. cited by applicant

Notice of Filing Date Accorded to Petition and Time for Filing Patent Owner Preliminary Response, IPR No. 2023-01252. cited by applicant
Petitioner's Explanation of Material Differences Between Petitions, IPR Nos. 2023-01251 and 2023-01252. cited by applicant
Petition For Inter Partes Review Of U.S. Pat. No. 11,298,056, IPR No. 2023-01252. cited by applicant
Declaration of Morten O. Jensen, Ph.D., Dr. Med, IPR No. 2023-01252. cited by applicant
Notice of Filing Date Accorded to Petition and Time for Filing Patent Owner Preliminary Response, IPR No. 2023-01251. cited by applicant
Petition For Inter Partes Review Of U.S. Pat. No. 11,298,056, IPR No. 2023-01251. cited by applicant
Declaration of Brian D. Gross, IPR No. 2023-01251. cited by applicant
Petitioner's Reply to Patent Owner's Response to Petition, IPR No. 2022-00605. cited by applicant
Supplemental Declaration of Gary D. Fletcher, Ph.D, IPR No. 2022-00605. cited by applicant
Declaration of Gary D. Fletcher, Ph.D, pp. 75-77, IPR No. 2022-00605. cited by applicant
Petition For Inter Partes Review Of U.S. Pat. No. 10,945,649, IPR No. 2022-00605. cited by applicant
Exhibit 3P to the Proposed Pretrial Order Abbott's Statement of Issues of Law Which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Exhibit 3D to the Proposed Pretrial Order Dexcom's Statement of Issues of Law Which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Exhibit 2P to the Proposed Pretrial Order Abbott's Statement of Issue of Fact Which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Exhibit 2D to Proposed Pretrial Order Dexcom's Statement of Contested Facts, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Exhibit 1 to the Proposed Pretrial Order Parties Joint Statement of Uncontroverted Facts, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Amended [Proposed] Final Pretrial Order, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Memorandum Opinion, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Order, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Appendix of Attachments and Exhibits for Plaintiffs' Opening Letter Brief in Support of Plaintiffs' Motion to Strike Defendant's New Claim Constructions, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Opening Letter Brief in Support of Plaintiffs' Motion to Strike Defendant's New Claim Constructions, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Dexcom's Letter Brief in Opposition to Abbott's Motion to Strike, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Plaintiffs' Motion to Strike Defendant's New Claim Constructions, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Transcript of Motion Hearing, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Defendant Dexcom, Inc.'s Reply Brief in Support of its Motion to Strike Abbott's Late-Disclosed Supplemental Declarations, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Appendix of Exhibits in Support of Dexcom, Inc.'s Opposition to Plaintiffs' Motion for Summary Judgement and Daubert Challenges—vol. 2, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Appendix of Exhibits in Support of Dexcom, Inc.'s Opposition to Plaintiffs' Motion for Summary Judgement and Daubert Challenges—vol. 1, Case No. 21-CV- 977-KAJ (D. Delaware)—Public

Version. cited by applicant
Defendant Dexcom, Inc.'s Appendix to Brief in Support of its Reply to Abbott Diabetes Care Inc. and Abbott Diabetes Care Limited's Opposition to Dexcom Inc.'s Motions for Summary Judgement, Case No. 21-CV-977-Kaj (D. Delaware)—Public Version. cited by applicant
Appendix of Exhibits and Attachments for Plaintiffs' Responsive Letter Brief In Opposition to Dexcom's Motion to Strike Expert Declarations (D.I. 408), Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Plaintiffs' Responsive Letter Brief in Opposition to Defendant's Motion to Strike Expert Declarations, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Defendant Dexcom, Inc.'s Appendix to Brief in Support of its Reply to Abbott Diabetes Care Inc. and Abbott Diabetes Care Limited's Opposition to Dexcom Inc.'s Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Defendant Dexcom, Inc.'s Opening Brief in Support of its Motion to Strike Abbott's Late-Disclosed Supplemental Declarations, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Defendant Dexcom, Inc.'s Reply in Support of Its Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Dexcom, Inc.'s Motion to Strike Plaintiffs' Untimely Expert Opinions, Case No. 21-CV-977-KAJ (D. Delaware). cited by applicant
Declaration of John L. Smith, PH.D., on Validity, in Support of Plaintiffs' Answering Brief in Opposition to Dexcom's Motions for Summary Judgement and Plaintiffs' Answering Brief in Opposition to Dexcom's Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version. cited by applicant
Declaration of John L. Smith, PH.D., Regarding Infringement, in Support of Plaintiffs' Answering Brief in Opposition to Dexcom's Motions for Summary Judgement and Plaintiffs' Answering Brief in Opposition to Dexcom's Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Appendix of Exhibits (vol. 3 of 3, Exhibits 151-171) for Plaintiffs' Answering Briefs In Opposition to Dexcom's Motions for Summary Judgement (D.I. 331) and to Exclude Expert Reports and Testimony (D.I. 337), Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Appendix of Exhibits (vol. 2 of 3, Exhibits 138-150) for Plaintiffs' Answering Briefs In Opposition to Dexcom's Motions for Summary Judgement (D.I. 331) and to Exclude Expert Reports and Testimony (D.I. 337), Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Appendix of Exhibits (vol. 1 of 3, Exhibits 98-137) for Plaintiffs' Answering Briefs In Opposition to Dexcom's Motions for Summary Judgement (D.I. 331) and to Exclude Expert Reports and Testimony (D.I. 337), Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Plaintiffs' Answering Brief In Opposition to Dexcom's Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Declaration of Dr. John E. Anderson in Opposition to Defendant Dexcom, Inc.'s Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Declaration of Dr. Eden M. Miller in Opposition to Defendant Dexcom, Inc.'s Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Declaration of Eric B. Hanson in Support of Dexcom's Opposition to Plaintiffs' Motion for

Summary Judgement and Daubert Challenges, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, Jun. 7, 2023. cited by applicant
Declaration of John Mastrototaro, Ph.D. in Support of Dexcom's Motion for Summary Judgement, Case No. 21- CV-977-KAJ (D. Delaware), May 19, 2023. cited by applicant
Defendant Dexcom, Inc.'s Opening Brief in Support of Its Motions to Exclude Expert Reports and Testimony, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 19, 2023. cited by applicant
Video-Recorded Deposition of Neil Sheehan, Ph.D, vol. I (pp. 1 to 221), Case No. 21-CV-977-KAJ (D. Delaware), May 4, 2023. cited by applicant
Video Deposition of Karl R. Leinsing, MSME, PE, vol. I, Case No. 21-CV-977-KAJ (D. Delaware), May 3, 2023. cited by applicant
Videotaped Deposition of John Mastrototaro, Ph.D, Case No. 21-CV-977-KAJ (D. Delaware), Apr. 26, 2023. cited by applicant
Video-Recorded Deposition of John Smith, Ph.D, Case No. 21-CV-977-KAJ (D. Delaware), Apr. 21, 2023. cited by applicant
Expert Report of John L. Smith, Ph.D., on Infringement of the Asserted Claims of U.S. Pat. No. 10,827,954, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 14, 2023. cited by applicant
Oral Argument Hearing Before Hon. Kent A. Jordan, U.S. Circuit Court Judge, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 9, 2023. cited by applicant
Defendant Dexcom, Inc.'s Supplemental Responses to Plaintiffs Abbott Diabetes Care Inc's. and Abbott Diabetes Care Limited's Notice of Rule 30(b)(6) Deposition, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 8, 2023. cited by applicant
Telephone Conference Before Kent A. Jordan, U.S. Circuit Court Judge, Case No. 21-CV-977-KAJ (D. Delaware) Letter to the Honorable Kent A. Jordan Regarding Discovery Disputes, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 3, 2023. cited by applicant
Defendant Dexcom, Inc.'s Notice of Deposition to Plaintiff Abbott Diabetes Care Limited, Case No. 21-CV-977-KAJ (D. Delaware), Aug. 19, 2022. cited by applicant
Defendant Dexcom, Inc.'s Notice of Deposition to Plaintiff Abbott Diabetes Care Inc., Case No. 21-CV-977-KAJ (D. Delaware, Aug. 19, 2022. cited by applicant
Plaintiffs' Proposed Claim Constructions, Case 21-CV-977-KAJ, May 27, 2022. cited by applicant
Plaintiffs' Identification of Claim Terms For Construction, Case 21-CV-977-KAJ (D. Delaware), May 13, 2022. cited by applicant
Joint Claim Construction Brief, Case 20-1679-RGA-JLH (D. Delaware), Feb. 11, 2022. cited by applicant
Plaintiff Dexcom, Inc.'s Amended Preliminary Disclosure of Asserted Claims and Infringement Contentions to Abbott Diabetes Care Inc. and Abbott Diabetes Care Sales Corp., Case 21-CV-690-ADA ((D. Texas), Jan. 5, 2022. cited by applicant
Order Denying Evenflo's Motion for Summary Judgement of Non-Infringement and Granting in Part and Denying in Part Wonderland's Motion for Partial Summary Judgement, Case 20-CV-727-JPM (D. Delaware), Dec. 6, 2022. cited by applicant
Findings of Fact and Conclusions of Law Regrading Subject Matter Eligibility of U.S. Pat. No. 6,975,308 Under 35 U.S.C. §101, Case 20-CV-101-ADA (D. Texas), Dec. 7, 2021. cited by applicant
Non-Final Office Action issued in U.S. Appl. No. 17/030,030, Dec. 17, 2020, Dec. 17, 2020. cited by applicant
Notice of Allowance issued in U.S. Appl. No. 15/963,828, Mar. 3, 2021. cited by applicant
Response to Non-Final Office Action filed in U.S. Appl. No. 15/963,828, Dec. 8, 2020. cited by applicant
Request Under 37 CRR 1.48(a) to Correct Inventorship filed in U.S. Appl. No. 15/963,828, Dec. 8, 2020. cited by applicant

Joint Declaration Under 37 C.F.R. 1.131 filed in Appl. U.S. Appl. No. 15/963,828, Nov. 30, 2020. cited by applicant
Non-Final Office Action issued in U.S. Appl. No. 14/884,622, Jun. 13, 2018. cited by applicant
Response to Restriction Requirement, and Acknowledgement Receipt, filed in U.S. Appl. No. 14/884,622, Apr. 5, 2018. cited by applicant
Email from John Shaw of Shaw & Keller dated May 16, 2023, 2 pages. cited by applicant
Notice of Filing Date Accorded to Petition and Time for Filing Patent Owner Preliminary Response, IPR No. 2024-00521, Feb. 29, 2024. cited by applicant
Petition for Inter Partes Review of U.S. Pat. No. 11,298,056, IPR No. 2024-00521, Feb. 9, 2024. cited by applicant
Decision Denying Institution of Inter Partes Review 35 U.S.C. § 314, IPR No. 2023-01252, Feb. 5, 2024. cited by applicant
Patent Owner's Response to Petitioner's Explanation of Material Differences Between Petitions, IPR Nos. 2023-01251 and 2023-01252, Jan. 18, 2024. cited by applicant
Patent Owner's Preliminary Response, IPR No. 2023-01252, Nov. 10, 2023. cited by applicant
Declaration of Brian D. Gross, IPR No. 2023-01252, Jul. 24, 2023. cited by applicant
Decision Granting Institution of Inter Partes Review 35 U.S.C. § 314, IPR No. 2023-01251, Feb. 5, 2024. cited by applicant
Patent Owner's Response to Petitioner's Explanation of Material Differences Between Petitions, IPR Nos. 2023-01251 and 2023-01252, Nov. 10, 2023. cited by applicant
Patent Owner's Preliminary Response, IPR No. 2023-01251, Nov. 10, 2023. cited by applicant
Petitioner's Explanation of Material Differences Between Petitions, IPR No. 2023-01251 and 2023-01252, Apr. 12, 2022. cited by applicant
Joint Letter to the Honorable Kent A. Jordan Regarding Additional Issues Related to the Upcoming Trial, Case No. 21-CV-977-KAJ (D. Delaware), Oct. 6, 2023. cited by applicant
[Joint Proposed] Verdict Form, Case No. 21-CV-977-KAJ (D. Delaware), Oct. 4, 2023. cited by applicant
Memorandum Opinion, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 22, 2023. cited by applicant
Bluetooth Basics, 2006, retrieved from https://web.archive.org/web/20060611161103/http://www.bluetooth.com/Bluetooth/Learn/Bas ics/, 1 page. cited by applicant
Declaration of Nathaniel E. Frank-White, Nov. 9, 2023, 28 pages. cited by applicant
Dexcom G4 Platinum Pediatric Continuous Glucose Monitoring System User's Guide, 2015, pp. 1-234. cited by applicant
Dexcom G5 Mobile Continuous Glucose Monitoring System FDA Premarket Approval (PMA), 2016, pp. 1-4. cited by applicant
Dexcom STS®-7 Continuous Glucose Monitoring System User's Guide, 2007, pp. 1-74. cited by applicant
“Discover Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System”, 2023, retrieved from https://www.dexcom.com/en-AE/g5-mobile-ae-english, 18 pages. cited by applicant
Explore The Monroe Street Market Community, retrieved from https://www.monroestreetmarket.com/floor-plans/apartment/B-231 on May 10, 2023, 2 pages. cited by applicant
Fcc Online Table of Frequency Allocations, Federal Communications Commission Office of Engineering and Technology Policy and Rules Division, 2022, 180 pages. cited by applicant
“FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System”, 2015, retrieved from https://www.dexcom.com/news/1257506247-fda-approves-dexcom-g5®- mobile-continuous-glucose-monitoring-system, 6 pages. cited by applicant
Hoss, U., et al., “Continuous glucose monitoring in the tissue: Do we really need to calibrate in-vivo?”, Feb. 28, 2009, pp. 1-21. cited by applicant

IPhone User Guide For IOS 8.4 Software, 2015, 196 pages. cited by applicant
Medtronic CareLink™ Personal, Getting Started, 2007, 20 pages. cited by applicant
Scheduling Order, IPR No. 2023-01251, Feb. 5, 2024. cited by applicant
Patent Owner's Sur-Reply in Support of the Patent Owner Preliminary Response, IPR No. 2023-01251, Dec. 18, 2023. cited by applicant
Petitioner's Reply to Patent Owner's Preliminary Response, IPR No. 2023-01251, Dec. 7, 2023. cited by applicant
[Proposed] Final Pretrial Order, vol. 3, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 12, 2024. cited by applicant
[Proposed] Final Pretrial Order, vol. 2, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 12, 2024. cited by applicant
Exhibit 7P to the Proposed Pretrial Order Abbott's Brief Summary of Opinion Testimony, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 7D to the Proposed Pretrial Order Dexcom's Brief Summary of Opinion Testimony, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 6P to the Proposed Pretrial Order Abbott's Deposition Designations, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 6D to the Proposed Pretrial Order Dexcom's Deposition Designations, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 5P to the Proposed Pretrial Order Abbott's List of Trial Exhibits, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 5D to the Proposed Pretrial Order Dexcom's List of Trial Exhibits, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 4 to the Proposed Pretrial Order Joint List of Trial Exhibits, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 3P to the Proposed Pretrial Order Abbott's Statement of Issues of Law Which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 3D to the Proposed Pretrial Order Dexcom's Statement of Issues of Law Which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 2P to the Proposed Pretrial Order Abbott's Statement of Issues of Fact Which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 2D to the Proposed Pretrial Order Dexcom's Statement of Contested Facts, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Exhibit 1 to the Proposed Pretrial Order Parties' Joint Statement of Uncontroverted Facts, Case No. 21-CV- 977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
[Proposed] Final Pretrial Order, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 4, 2024. cited by applicant
Video Deposition of Laura B. Stamm, vol. 1, Case No. 21-CV-977-KAJ (D. Delaware), Apr. 28, 2023. cited by applicant
Telephonic Proceedings, Case No. 21-CV-977-KAJ (D. Delaware), Apr. 5, 2023. cited by applicant
Report of Karl R. Leinsing, MSME, PE, Regarding Infringement of U.S. Pat. Nos. 10,973,443, 11,000,216, 10,881,341, 10,959,654, 10,945,649, and 11,013,440, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 14, 2023. cited by applicant
Defendant Dexcom, Inc.'s Supplemental Responses and Objections to Plaintiffs Abbott Diabetes Care Inc.'s and Abbott Diabetes Care Limited's Notice of Rule 30(b)(6) Deposition, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 28, 2023. cited by applicant
Plaintiff's Second Set of Interrogatories (Nos. 10-33) to Defendant, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 8, 2022. cited by applicant
Plaintiff's First Set of Interrogatories (Nos. 1-9) to Defendant, Case No. 21-CV-977-KAJ (D. Delaware), Nov. 10, 2021. cited by applicant

List of Challenged Claims, IPR No. 2024-00521, Feb. 9, 2024. cited by applicant
Declaration of Brian D. Gross, IPR No. 2024-00521, Feb. 9, 2024. cited by applicant
Petitioner's Request for Refund of the Post-Institution Fee, IPR No. 2023-01252, Feb. 21, 2024. cited by applicant
Notice of Stipulation, IPR No. 2023-01251, Mar. 22, 2024. cited by applicant
Declaration of Arie Pellikaan, IPR No. 2023-01251, Mar. 5, 2024. cited by applicant
Patent Owner's Objections to Admissibility of Evidence Served with Petition, IPR No. 2023-01251, Feb. 20, 2024. cited by applicant
Petitioner's Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8(a)(3), IPR No. 2023-01251, Feb. 19, 2024. cited by applicant
Abbott's Initial Claim Charts, Case No. 23-239-KAJ (D. Delaware), Dec. 20, 2023. cited by applicant
Scheduling Order, Case No. 23-239-KAJ (D. Delaware), Sep. 19, 2023. cited by applicant
[Joint Proposed] Final Jury Instructions, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 17, 2024. cited by applicant
[Joint Proposed] Final Jury Instructions, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 7P to the Proposed Pretrial Order Abbott's Brief Summary of Opinion Testimony, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 7D to the Proposed Pretrial Order Dexcom's Brief Summary of Opinion Testimony, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 6P to the Proposed Pretrial Order Abbott's Deposition Designation, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 6D to the Proposed Pretrial Order Dexcom's Deposition Designation, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 5P to the Proposed Pretrial Order Abbott's List of Trial Exhibits, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 5D to the Proposed Pretrial Order Dexcom's List of Trial Exhibits, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 3P to the Proposed Pretrial Order Abbott's Statement of Issues of Law which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 3D to the Proposed Pretrial Order Dexcom's Statement of Issues of Law which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 2P to the Proposed Pretrial Order Abbott's Statement of Issues of Fact which Remain to be Litigated, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 2D to the Proposed Pretrial Order Dexcom's Statement of Contested Facts, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Exhibit 1 to the Proposed Pretrial Order Parties' Joint Statement of Uncontroverted Facts, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
[Proposed] Final Pretrial Order, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 7, 2024. cited by applicant
Joint Stipulation and [Proposed] Order Regarding Dismissal of Certain Asserted Patent Claims, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 1, 2024. cited by applicant
Letter to the Honorable Kent A. Jordan from Nathan R. Hoeschen Regarding Pretrial Order, Redacted, Public Version, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 15, 2024. cited by applicant
Defendant Dexcom, Inc.'s Notice Pursuant to 35 U.S.C. § 282, Case No. 21-CV-977-KAJ (D. Delaware), Feb. 9, 2024. cited by applicant
Letter to Kent A. Jordan, Case No. 21-CV-977-KAJ (D. Delaware), , Feb. 2, 2024. cited by applicant

[Joint Proposed] Final Jury Instructions, Case No. 21-CV-977-KAJ (D. Delaware), Jan. 31, 2024. cited by applicant
Affidavit of Nathaniel E. Frank-White, May 18, 2023, 108 pages. cited by applicant
Affadavit of Nathaniel E Frank-White dated Aug. 16, 2024, 31 pages. cited by applicant
Almurashi, A. M., et al., "Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases", J. Indian Inst. Sci., 2023, pp. 1-26. cited by applicant
American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Care, 2005, vol. 28, Suppl. 1, pp. S4-S36. cited by applicant
American Diabetes Association Standards of Medical Care in Diabetes—2006, Diabetes Care, 2006, vol. 29, Suppl. 1, pp. S4-S41. cited by applicant
American Diabetes Association Standards of Medical Care in Diabetes—2007, Diabetes Care, 2007, vol. 30, Suppl. 1, pp. S4-S42. cited by applicant
Atmel® ATmega169P Datasheet, 2010, 395 pages. cited by applicant
Atmel® Products Selector Guide, 2008, 90 pages. cited by applicant
Bergenstal, R. M., et al., "Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes", The New England Journal of Medicine, 2010, vol. 363, No. 4, pp. 311-320. cited by applicant
Bluetooth Specification, Health Device Profile, 2008, pp. 1-44. cited by applicant
Cappon, G., et al., "Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications", Diabetes & Metabolism Journal, 2019, vol. 43, pp. 383-397. cited by applicant
Cather, D. E., "CGM Frustrations Survey", 2020, 36 pages. cited by applicant
Das, S. D., et al., "Review—Electrochemistry and Other Emerging Technologies for Continuous Glucose Monitoring Devices", ECS Sensors Plus, 2022, 19 pages. cited by applicant
Dawson, D. M., "The Integration of Ground-based Real-time Telemetry Processing, On-board Chapter 10 Aircraft Data Recorders, and 802.11G Links", International Telemetering Conference Proceedings, 2005, retrieved from http://hdl.handle.net/10150/604914, 4 pages. cited by applicant
Design Concepts Project Status Update, Glucose Sensor Applicator Dexcom (project #2554), 2014, 5 pages. cited by applicant
Dexcom G5 Mobile System User Guide, 2016, pp. 1-371. cited by applicant
Dexcom G6 Continuous Glucose Monitoring (CGM) System Section 510(k) Approval, 2022, 7 pages. cited by applicant
Dexcom G6 Continuous Glucose Monitoring System User Guide, 2022, pp. 1-341. cited by applicant
Dexcom Seven® Plus Continuous Glucose Monitoring System User's Guide, 2011, pp. 1-144. cited by applicant
Dexcom™ STSTM-7 Continuous Glucose Monitoring System FCC Submission, 2006, 3 pages. cited by applicant
Email from Christopher M Dougherty dated Dec. 17, 2019, 68 pages. cited by applicant
FreeStyle Libre 2 HCP Pulse Report, 2021, 13 pages. cited by applicant
FreeStyle Libre 3 User's Manual, 2022-2023, pp. iv-241. cited by applicant
Freestyle Navigator User's Guide, 2008, pp. 1-195. cited by applicant
Garg, S., et al., "Flash Glucose Monitoring: The Future Is Here", Diabetes Technology & Therapeutics, 2017, vol. 19, Suppl 2, pp. S-1-S-3. cited by applicant
Grace, R., et al., Vehicle Network Concept Demonstration », International Telemetering Conference Proceedings, 2005, retrieved from http://hdl.handle.net/10150/604790, 10 pages. cited by applicant
Hirsch, I. B., et al., "Role of Continuous Glucose Monitoring in Diabetes Treatment", American Diabetes Association, 2018, p. 1.24. cited by applicant
Hodack, D., "Implementing Inet and the Operational Issues Involved", International Telemetering

Conference Proceedings, 2008, retrieved from http://hdl.handle.net/10150/606171, 7 pages. cited by applicant
International Diabetes Device 2022 Blue Book, Seagrove Partners, 142 pages. cited by applicant
Johnson, D. A., et al., Electrochemical Methods for Neuroscience, Chapter 20, Telemetry for Biosensor Systems, 2007, 13 pages. cited by applicant
The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, "Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes", The New England Journal of Medicine, 2008, vol. 359, No. 14, pp. 1464-1476. cited by applicant
Mastrototaro, J., et al., "Accuracy of Real-Time Continuous Glucose Monitoring in the Mini-Med Paradigm System," Diabetes, 2007, vol. 56, Suppl. 1, p. A112. cited by applicant
Mathis, M., et al., "TCP Selective Acknowledgement Options", Network Working Group, 1996, 12 pages. cited by applicant
Medtronic Carelink® Personal Quick Start Guide, 2015, 2 pages. cited by applicant
Medtronic MiniMed Guardian Rt Fda Premarket Approval (PMA), 2005, pp. 1-6. cited by applicant
Medtronic MiniMed Guardian RT Summary of Safety and Effectiveness Data, 2005, 13 pages. cited by applicant
Medtronic MiniMed Paradigm® REAL-Time Insulin Pump User Guide, 2007, pp. 1-164. cited by applicant
National Diabetes Statistics Report, Centers for Disease Control and Prevention, 2023, retrieved from https://www.cdc.gov/diabetes/data/statistics-report/index.html, 15 pages. cited by applicant
Sohraby, K., et al., Wireless Sensor Networks: Technology, Protocols, and Application, 2007, pp. xi-306. cited by applicant
Wolpert, H., "Establishing a Continuous Glucose Monitoring Program", Journal of Diabetes Science and Technology, 2008, vol. 2, No. 2, pp. 307-310. cited by applicant
Wright, Jr., E., et al., "Ambulatory Glucose Profiling", The Journal of Family Practice, 2015, vol. 64. No. 12, Supplement, pp. 544-547. cited by applicant
ZigBee Specification, 2007, pp. i-576. cited by applicant
14805745.8 Notice of Opposition, Jul. 26, 2021. cited by applicant
Decision Granting Institution of Inter Partes Review, IPR No. 2024-00521, Aug. 22, 2024. cited by applicant
Patent Owner's Objections To Admissibility of Evidence Served With Petition, IPR No. 2024-00521, Sep. 6, 2024. cited by applicant
Patent Owner's Preliminary Response, IPR No. 2024-00521, May 29, 2024. cited by applicant
Termination, IPR No. 2023-01251, Jan. 8, 2025. cited by applicant
Joint Motion To Terminate Proceeding, IPR No. 2023-01251, Jan. 6, 2025. cited by applicant
Record of Oral Hearing, Paper #39, IPR No. 2023-01251, Nov. 25, 2024. cited by applicant
Record of Oral Hearing, Paper 38, IPR No. 2023-01251, Nov. 25, 2024. cited by applicant
Petitioner Dexcom's Demonstratives, IPR No. 2023-01251, Nov. 4, 2024. cited by applicant
Patent Owner's Demonstratives, IPR No. 2023-01251, Oct. 30, 2024. cited by applicant
Patent Owner's Updated Exhibit List, IPR No. 2023-01251, Oct. 30, 2024. cited by applicant
Patent Owner's Surreply to Petitioner's Reply, IPR No. 2023-01251, Oct. 21, 2024. cited by applicant
Deposition of Andrew Ahmann, MD, IPR No. 2023-01251, Oct. 11, 2024. cited by applicant
Deposition of Brian D. Gross, IPR No. 2023-01251, Oct. 10, 2024. cited by applicant
Declaration of Arie Pellikaan, IPR No. 2023-01251, Sep. 27, 2024. cited by applicant
Patent Owner's Objections to Admissibility of Evidence Served With Petitioner's Reply to Patent Owner's Response, IPR No. 2023-01251, Sep. 13, 2024. cited by applicant
Reply Declaration of Brian D. Gross, IPR No. 2023-01251, Sep. 6, 2024. cited by applicant
Petitioner's Reply to Patent Owner's Response, IPR No. 2023-01251, Sep. 6, 2024. cited by

applicant
Deposition of Eugene E. Wright, IPR No. 2023-01251, Jul. 25, 2024. cited by applicant
Deposition of Aaron Striegel, Ph.D, IPR No. 2023-01251, Jul. 24, 2024. cited by applicant
Declaration of Holly Mack, IPR No. 2023-01251, Jun. 13, 2024. cited by applicant
Petitioner's Objections to Patent Owner's Response, IPR No. 2023-01251, May 30, 2024. cited by applicant
Notice of Stipulation, IPR No. 2023-01251, May 24, 2024. cited by applicant
Declaration of Aaron Striegel, Ph.D., in Support of Patent Owner's Response IPR No. 2023-01251, May 22, 2024. cited by applicant
Patent Owner's Response, IPR No. 2023-01251, May 22, 2024. cited by applicant
Deposition of Brian D. Gross, IPR No. 2023-01251, May 2, 2024. cited by applicant
Patent Owner's Updated Notice of Deposition of Brian D. Gross, IPR No. 2023-01251, Apr. 24, 2024. cited by applicant
Notice of Stipulation, IPR No. 2023-01251, Apr. 24, 2024. cited by applicant
Declaration of Andrew Ahmann M.D. in Support of Dexcom's Reply, IPR No. 2023-01251, Apr. 9, 2024. cited by applicant
Patent Owner's Notice of Deposition of Brian D. Gross, IPR No. 2023-01251, Apr. 2, 2024. cited by applicant
Notice of Final Written Decision re Inter Partes Review of the '649 Patent, IPR No. 2022-00605, Jul. 13, 2025. cited by applicant
Final Written Decision, IPR No. 2022-00605, Jul. 10, 2025. cited by applicant
Record of Oral Hearing, IPR No. 2022-00605, Apr. 26, 2023. cited by applicant
Joint Claim Construction Chart, Case No. 23-239-KAJ, Mar. 21, 2024. cited by applicant
Dexcom, Inc's Initial Proposed Claim Constructions, Case No. 23-239-KAJ, Feb. 28, 2024. cited by applicant
Complaint, Case No. 23-239-KAJ, Mar. 3, 2023. cited by applicant
Dexcom's Notice of Appeal, Case No. 21-CV-977-KAJ, Nov. 26, 2024. cited by applicant
Memorandum Opinion, Unsealed, Case No. 21-CV-977-KAJ, Nov. 21, 2024. cited by applicant
Order, Case No. 21-CV-977-KAJ, Nov. 21, 2024. cited by applicant
Order, Case No. 21-CV-977-KAJ, Nov. 13, 2024. cited by applicant
Memorandum Opinion, Sealed, Case No. 21-CV-977-KAJ, Nov. 13, 2024. cited by applicant
Exhibit 056-22 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-21 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-20 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-19 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-18 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-17 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-16 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-15 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-14 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-13 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D.

Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-12 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-11 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-10 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-9 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-8 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-7 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-5 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-4 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Exhibit 056-3 from DexCom, Inc.'s Final Invalidity Contentions, Case No. 21-CV-977-KAJ (D. Delaware), Sep. 19, 2024. cited by applicant
Reference PTX-0619 (Excerpted) of Dexcom's Reply in Support of Its Renewed Motion for Judgment as a Matter of Law and Motion for a New Trial, Case No. 21-CV-977-KAJ, Jul. 12, 2024. cited by applicant
Dexcom's Reply in Support of Its Renewed Motion for Judgment as a Matter of Law and Motion for a New Trial, Case No. 21-CV-977-KAJ, Jul. 12, 2024. cited by applicant
Plaintiffs' Reply Brief in Support of Their Motion for Judgment as a Matter of Law Under Federal Rule of Civil Procedure 50 and for a New Trial Under Federal Rule of Civil Procedure 59, Case No. 21-CV-977-KAJ (D. Delaware), Jul. 12, 2024. cited by applicant
Reference DX4961 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX4756 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX4721 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX4720 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX4719 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX1550 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX0179 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX0012 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D.

Delaware), Jun. 21, 2024. cited by applicant
Reference DDX-12 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DDX-8 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DDX-5 of Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Defendant Dexcom, Inc.'s Memorandum in Opposition to Plaintiffs' Motion for Judgment as a Matter of Law Or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Jun. 21, 2024. cited by applicant
Reference DX4726 of Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 24, 2024. cited by applicant
Reference DX4721 of Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 24, 2024. cited by applicant
Reference DX4719 Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), May 24, 2024. cited by applicant
Reference DX0381 of Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 24, 2024. cited by applicant
Reference DX0189 of Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 24, 2024. cited by applicant
Reference DX0183 of Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 24, 2024. cited by applicant
Reference DX0012 of Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 24, 2024. cited by applicant
Reference PDX07 of Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 24, 2024. cited by applicant
Defendant Dexcom, Inc.'s Appendix to Motion for Judgment as a Matter of Law or, Alternatively, for a New Trial, Case No. 21-CV-977-KAJ (D. Delaware), May 24, 2024. cited by applicant
Plaintiffs' Opening Brief in Support of Their Motion for Judgment as a Matter of Law Under Federal Rule of Civil Procedure 50 and for a New Trial Under Federal Rule of Civil Procedure 59, Case No. 21-CV-977-KAJ (D. Delaware), May 24, 2024. cited by applicant
Defendant Dexcom, Inc.'s Opening Brief in Support of Its Renewed Motion for Judgment as a Matter of Law and Motion for New Trial, Case No. 21-CV-977-KAJ (D. Delaware), May 24, 2024. cited by applicant
Joint Status Report, Case No. 21-CV-977-KAJ (D. Delaware), May 7, 2024. cited by applicant
Plaintiffs' Renewed Motion for Judgment as a Matter of Law, Case No. 21-CV-977-KAJ (D. Delaware), Apr. 19, 2024. cited by applicant
Dexcom, Inc.'s Renewed Motion for Judgment as a Matter of Law and Motion for New Trial, Case No. 21-CV-977-KAJ (D. Delaware), Apr. 19, 2024. cited by applicant

Joint Status Report, Case No. 21-CV-977-KAJ (D. Delaware), Apr. 5, 2024. cited by applicant
Transcript of Jury Trial, vol. X, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 22, 2024. cited by applicant
Transcript of Jury Trial, vol. IX, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 21, 2024. cited by applicant
Transcript of Jury Trial, vol. VIII, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 20, 2024. cited by applicant
Transcript of Jury Trial, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 19, 2024. cited by applicant
Transcript of Jury Trial, vol. VI, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 18, 2024. cited by applicant
Transcript of Jury Trial, vol. V, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 15, 2024. cited by applicant
Transcript of Jury Trial, vol. IV, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 14, 2024. cited by applicant
Transcript of Jury Trial, vol. III, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 13, 2024. cited by applicant
Transcript of Jury Trial, vol. II, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 12 2024. cited by applicant
Transcript of Jury Trial, vol. I, Case No. 21-CV-977-KAJ (D. Delaware), Mar. 11, 2024. cited by applicant
Declaration of Karl R. Leinsing, Msme, Pe, in Support of Abbott's Motion for Summary Judgement, Case No. 21-CV-977-KAJ (D. Delaware)—Public Version, May 19, 2023. cited by applicant
Memorandum Opinion and Order, Case No. 21-209-WCB, Mar. 3, 2023. cited by applicant
Declaration of Eugene E. Wright, Jr. MD, IPR No. 2024-00521., Dec. 6, 2024. cited by applicant
Declaration of Aaron Striegel, Ph.D, in Support of Patent Owner's Response, IPR No. 2024-00521., Dec. 6, 2024. cited by applicant
Deposition of Brian D. Gross, IPR No. 2024-00521. cited by applicant

---

Primary Examiner: Lin; Jerry

Attorney, Agent or Firm: ONE LLP

Background/Summary

RELATED APPLICATIONS (1) The present application is a continuation of U.S. patent application Ser. No. 17/411,154, filed Aug. 25, 2021, which is a continuation of U.S. patent application Ser. No. 17/245,719, filed Apr. 30, 2021, now U.S. patent Ser. No. 11/116,431, which is a continuation of U.S. patent application Ser. No. 16/228,910, filed Dec. 21, 2018, now U.S. Pat. No. 11,013,431, which is a continuation of U.S. patent application Ser. No. 15/061,774, filed Mar. 4, 2016, now U.S. Pat. No. 10,194,844, which is a continuation of U.S. patent application Ser. No. 13/925,694, filed Jun. 24, 2013, now U.S. Pat. No. 9,310,230, which is a continuation of U.S. patent application Ser. No. 12/769,635, filed Apr. 28, 2010, now U.S. Pat. No. 8,483,967, which claims the benefit of U.S. Provisional Patent Application No. 61/173,600, filed Apr. 29, 2009, the disclosures of all of which are incorporated herein by reference in their entireties for all purposes.

BACKGROUND
(1) Analyte, e.g., glucose monitoring systems including continuous and discrete monitoring

systems generally include a small, lightweight battery powered and microprocessor controlled system which is configured to detect signals proportional to the corresponding measured glucose levels using an electrometer. RF signals may be used to transmit the collected data. One aspect of certain analyte monitoring systems includes a transcutaneous or subcutaneous analyte sensor configuration which is, for example, at least partially positioned through the skin layer of a subject whose analyte level is to be monitored. The sensor may use a two or three-electrode (work, reference and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.

(2) An analyte sensor may be configured so that a portion thereof is placed under the skin of the patient so as to contact analyte of the patient, and another portion or segment of the analyte sensor may be in communication with the transmitter unit. The transmitter unit may be configured to transmit the analyte levels detected by the sensor over a wireless communication link such as an RF (radio frequency) communication link to a receiver/monitor unit. The receiver/monitor unit may perform data analysis, among other functions, on the received analyte levels to generate information pertaining to the monitored analyte levels.

SUMMARY

(3) Devices and methods for analyte monitoring, e.g., glucose monitoring, and/or therapy management system including, for example, medication infusion devices are provided. Embodiments include transmitting information from a first location to a second, e.g., using a telemetry system such as RF telemetry. Systems herein include continuous analyte monitoring systems, discrete analyte monitoring system, and therapy management systems.

(4) Embodiments include receiving sensor data from an analyte sensor of a sensor monitoring system, processing the received sensor data with time corresponding calibration data, outputting the processed sensor data, detecting one or more adverse conditions associated with the sensor monitoring system, disabling the output of the sensor data during a adverse condition time period, determining that the one or more detected adverse conditions is no longer present in the sensor monitoring system, retrieving the sensor data during the adverse condition time period, processing the retrieved sensor data during the adverse condition time period, and outputting the processed retrieved sensor data.

(5) Embodiments include detecting a condition unsuitable for calibration of an analyte sensor for a predetermined time period, disabling output of information associated with the analyte sensor, determining a successful calibration of the analyte sensor, retrieving one or more parameters associated with the successful calibration, processing sensor data during the time period of disabled output of information with the one or more parameters associated with the successful calibration, and displaying the processed sensor data for the time period of disabled information output.

(6) Embodiments include an interface configured to receive sensor data, a first memory configured to store the received sensor data, a processor coupled to the memory and configured to process the stored sensor data, a second memory coupled to the processor and configured to store the processed sensor data, and a display unit coupled to the second memory and configured to display the processed sensor data, where the processor is further configured to detect a condition unsuitable for calibration of a sensor for a predetermined time period, disable display of processed sensor data, determine a successful calibration of the sensor, retrieve one or more parameters associated with the successful calibration, process the sensor data during the time period of disabled display of sensor data with the one or more parameters associated with the successful calibration, and display the processed sensor data for the time period of disabled information output.

(7) These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.

INCORPORATION BY REFERENCE

(8) The following patents, applications and/or publications are incorporated herein by reference for

all purposes: U.S. Pat. Nos. 4,545,382; 4,711,245; 5,262,035; 5,262,305; 5,264,104; 5,320,715; 5,509,410; 5,543,326; 5,593,852; 5,601,435; 5,628,890; 5,820,551; 5,822,715; 5,899,855; 5,918,603; 6,071,391; 6,103,033; 6,120,676; 6,121,009; 6,134,461; 6,143,164; 6,144,837; 6,161,095; 6,175,752; 6,270,455; 6,284,478; 6,299,757; 6,338,790; 6,377,894; 6,461,496; 6,503,381; 6,514,460; 6,514,718; 6,540,891; 6,560,471; 6,579,690; 6,591,125; 6,592,745; 6,600,997; 6,605,200; 6,605,201; 6,616,819; 6,618,934; 6,650,471; 6,654,625; 6,676,816; 6,730,200; 6,736,957; 6,746,582; 6,749,740; 6,764,581; 6,773,671; 6,881,551; 6,893,545; 6,932,892; 6,932,894; 6,942,518; 7,167,818; and 7,299,082; U.S. Published Application Nos. 2004/0186365; 2005/0182306; 2007/0056858; 2007/0068807; 2007/0227911; 2007/0233013; 2008/0081977; 2008/0161666; and 2009/0054748; U.S. patent application Ser. Nos. 11/831,866; 11/831,881; 11/831,895; 12/102,839; 12/102,844; 12/102,847; 12/102,855; 12/102,856; 12/152,636; 12/152,648; 12/152,650; 12/152,652; 12/152,657; 12/152,662; 12/152,670; 12/152,673; 12/363,712; 12/131,012; 12/242,823; 12/363,712; 12/393,921; 12/495,709; 12/698,124; 12/699,653; 12/699,844; 12/714,439; 12/761,372; and 12/761,387 and U.S. Provisional Application Nos. 61/230,686 and 61/227,967.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. **1** illustrates a block diagram of a data monitoring and management system for practicing one or more embodiments of the present disclosure;

(2) FIG. **2** is a block diagram of the transmitter unit of the data monitoring and management system shown in FIG. **1** in accordance with one embodiment of the present disclosure;

(3) FIG. **3** is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. **1** in accordance with one embodiment of the present disclosure;

(4) FIG. **4** illustrates analyte sensor data processing in accordance with one embodiment of the present disclosure;

(5) FIG. **5** illustrates analyte sensor data processing in accordance with one embodiment of the present disclosure;

(6) FIG. **6** illustrates backfilling gaps in sensor data in one embodiment of the present disclosure; and

(7) FIGS. **7**A and **7**B illustrate backfill of gaps of a period of uncalibrated sensor data in one embodiment.

DETAILED DESCRIPTION

(8) Before the present disclosure is described in additional detail, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

(9) Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

(10) Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

(11) It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.

(12) The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

(13) As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.

(14) The figures shown herein are not necessarily drawn to scale, with some components and features being exaggerated for clarity.

(15) As described in further detail below, in accordance with the various embodiments of the present disclosure, there is provided a method and system for positioning a controller unit within a transmission range for close proximity communication, transmitting one or more predefined close proximity commands, and receiving a response packet in response to the transmitted one or more predefined close proximity commands. For example, in one aspect, close proximity communication includes short range wireless communication between communication components or devices, where the communication range is limited to about 10 inches or less, about 5 inches or less, or about 2 inches or less, or other suitable, short range or distance between the devices. The close proximity wireless communication in certain embodiments includes a bi-directional communication where a command sending communication device, when positioned within the short communication range or in close proximity to the command receiving communication device, is configured to transmit one or more commands to the command receiving communication device (for example, when a user activates or actuates a transmit command button or switch). In response, the command receiving communication device may be configured to perform one or more routines associated with the received command, and/or return or send back a response data packet or signal to the command sending communication device. Example of such functions and or commands may include, but not limited to activation of certain functions or routines such as analyte related data processing, and the like.

(16) FIG. **1** illustrates a data monitoring and management system such as, for example, analyte (e.g., glucose) monitoring system **100** in accordance with one embodiment of the present disclosure. The subject invention is further described primarily with respect to a glucose monitoring system for convenience and such description is in no way intended to limit the scope of the invention. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes, e.g., lactate, and the like.

(17) Analytes that may be monitored include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. More than one analyte may be monitored by a single system, e.g., a single analyte sensor.

(18) The analyte monitoring system **100** includes a sensor unit **101**, a data processing and transmitter unit **102** coupleable to the sensor unit **101**, and a primary receiver unit **104** which is

configured to communicate with the data processing and transmitter unit **102** via a bi-directional communication link **103**. The primary receiver unit **104** may be further configured to transmit data to a data processing terminal **105** for evaluating the data received by the primary receiver unit **104**. Moreover, the data processing terminal **105** in one embodiment may be configured to receive data directly from the data processing and transmitter unit **102** via a communication link which may optionally be configured for bi-directional communication. Accordingly, data processing and transmitter unit **102** and/or receiver unit **104** may include a transceiver.

(19) Also shown in FIG. **1** is an optional secondary receiver unit **106** which is operatively coupled to the communication link and configured to receive data transmitted from the data processing and transmitter unit **102**. Moreover, as shown in the Figure, the secondary receiver unit **106** is configured to communicate with the primary receiver unit **104** as well as the data processing terminal **105**. Indeed, the secondary receiver unit **106** may be configured for bi-directional wireless communication with each or one of the primary receiver unit **104** and the data processing terminal **105**. As discussed in further detail below, in one embodiment of the present disclosure, the secondary receiver unit **106** may be configured to include a limited number of functions and features as compared with the primary receiver unit **104**. As such, the secondary receiver unit **106** may be configured substantially in a smaller compact housing or embodied in a device such as a wrist watch, pager, mobile phone, PDA, for example. Alternatively, the secondary receiver unit **106** may be configured with the same or substantially similar functionality as the primary receiver unit **104**. The receiver unit may be configured to be used in conjunction with a docking cradle unit, for example for one or more of the following or other functions: placement by bedside, for re-charging, for data management, for night time monitoring, and/or bi-directional communication device.

(20) In one aspect sensor unit **101** may include two or more sensors, each configured to communicate with data processing and transmitter unit **102**. Furthermore, while only one, data processing and transmitter unit **102**, communication link **103**, and data processing terminal **105** are shown in the embodiment of the analyte monitoring system **100** illustrated in FIG. **1**. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system **100** may include one or more sensors, multiple transmitter units **102**, communication links **103**, and data processing terminals **105**. Moreover, within the scope of the present disclosure, the analyte monitoring system **100** may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each device is configured to be uniquely identified by each of the other devices in the system so that communication conflict is readily resolved between the various components within the analyte monitoring system **100**.

(21) In one embodiment of the present disclosure, the sensor unit **101** is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor unit **101** may be configured to continuously sample the analyte level of the user and convert the sampled analyte level into a corresponding data signal for transmission by the data processing and transmitter unit **102**. In certain embodiments, the data processing and transmitter unit **102** may be physically coupled to the sensor unit **101** so that both devices are integrated in a single housing and positioned on the user's body. The data processing and transmitter unit **102** may perform data processing such as filtering and encoding on data signals and/or other functions, each of which corresponds to a sampled analyte level of the user, and in any event data processing and transmitter unit **102** transmits analyte information to the primary receiver unit **104** via the communication link **103**. Examples of such integrated sensor and transmitter units can be found in, among others, U.S. patent application Ser. No. 12/698,124, incorporated herein by reference.

(22) In one embodiment, the analyte monitoring system **100** is configured as a one-way RF communication path from the data processing and transmitter unit **102** to the primary receiver unit **104**. In such embodiment, the data processing and transmitter unit **102** transmits the sampled data signals received from the sensor unit **101** without acknowledgement from the primary receiver unit **104** that the transmitted sampled data signals have been received. For example, the data processing

and transmitter unit **102** may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals) after the completion of the initial power on procedure. Likewise, the primary receiver unit **104** may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals. Alternatively, the analyte monitoring system **100** may be configured with a bi-directional RF (or otherwise) communication between the data processing and transmitter unit **102** and the primary receiver unit **104**.

(23) Additionally, in one aspect, the primary receiver unit **104** may include two sections. The first section is an analog interface section that is configured to communicate with the data processing and transmitter unit **102** via the communication link **103**. In one embodiment, the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from the data processing and transmitter unit **102**, which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter. The second section of the primary receiver unit **104** is a data processing section which is configured to process the data signals received from the data processing and transmitter unit **102** such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery.

(24) In operation, upon completing the power-on procedure, the primary receiver unit **104** is configured to detect the presence of the data processing and transmitter unit **102** within its range based on, for example, the strength of the detected data signals received from the data processing and transmitter unit **102** and/or a predetermined transmitter identification information. Upon successful synchronization with the corresponding data processing and transmitter unit **102**, the primary receiver unit **104** is configured to begin receiving from the data processing and transmitter unit **102** data signals corresponding to the user's detected analyte level. More specifically, the primary receiver unit **104** in one embodiment is configured to perform synchronized time hopping with the corresponding synchronized data processing and transmitter unit **102** via the communication link **103** to obtain the user's detected analyte level.

(25) Referring again to FIG. **1**, the data processing terminal **105** may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs)), and the like, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal **105** may further be connected to a data network (not shown) for storing, retrieving and updating data corresponding to the detected analyte level of the user.

(26) Within the scope of the present disclosure, the data processing terminal **105** may include an infusion device such as an insulin infusion pump (external or implantable) or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the receiver unit **104** for receiving, among others, the measured analyte level. Alternatively, the receiver unit **104** may be configured to integrate or otherwise couple to an infusion device therein so that the receiver unit **104** is configured to administer insulin therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the data processing and transmitter unit **102**.

(27) Additionally, the data processing and transmitter unit **102**, the primary receiver unit **104** and the data processing terminal **105** may each be configured for bi-directional wireless communication such that each of the data processing and transmitter unit **102**, the primary receiver unit **104** and the data processing terminal **105** may be configured to communicate (that is, transmit data to and receive data from) with each other via the wireless communication link **103**. More specifically, the data processing terminal **105** may in one embodiment be configured to receive data directly from the data processing and transmitter unit **102** via the communication link **103**, where the communication link **103**, as described above, may be configured for bi-directional communication.

(28) In this embodiment, the data processing terminal **105** which may include an insulin pump, may be configured to receive the analyte signals from the data processing and transmitter unit **102**,

and thus, incorporate the functions of the receiver **104** including data processing for managing the patient's insulin therapy and analyte monitoring. In one embodiment, the communication link **103** may include one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPPA requirements) while avoiding potential data collision and interference.

(29) FIG. **2** is a block diagram of the transmitter of the data monitoring and detection system shown in FIG. **1** in accordance with one embodiment of the present disclosure. Referring to the Figure, the data processing and transmitter unit **102** in one embodiment includes an analog interface **201** configured to communicate with the sensor unit **101** (FIG. **1**), a user input **202**, and a temperature measurement section **203**, each of which is operatively coupled to a transmitter processor **204** such as a central processing unit (CPU). As can be seen from FIG. **2**, there are provided four contacts, three of which are electrodes—work electrode (W) **210**, guard contact (G) **211**, reference electrode (R) **212**, and counter electrode (C) **213**, each operatively coupled to the analog interface **201** of the data processing and transmitter unit **102** for connection to the sensor unit **101** (FIG. **1**). In one embodiment, each of the work electrode (W) **210**, guard contact (G) **211**, reference electrode (R) **212**, and counter electrode (C) **213** may be made using a conductive material that is either printed or etched or ablated, for example, such as carbon which may be printed, or a metal such as a metal foil (e.g., gold) or the like, which may be etched or ablated or otherwise processed to provide one or more electrodes. Fewer or greater electrodes and/or contact may be provided in certain embodiments.

(30) Further shown in FIG. **2** are a transmitter serial communication section **205** and an RF transmitter **206**, each of which is also operatively coupled to the transmitter processor **204**. Moreover, a power supply **207** such as a battery is also provided in the data processing and transmitter unit **102** to provide the necessary power for the data processing and transmitter unit **102**. In certain embodiments, the power supply **207** also provides the power necessary to power the sensor **101**. In other embodiments, the sensor is a self-powered sensor, such as the sensor described in U.S. patent application Ser. No. 12/393,921, incorporated herein by reference. Additionally, as can be seen from the Figure, clock **208** is provided to, among others, supply real time information to the transmitter processor **204**.

(31) In one embodiment, a unidirectional input path is established from the sensor unit **101** (FIG. **1**) and/or manufacturing and testing equipment to the analog interface **201** of the data processing and transmitter unit **102**, while a unidirectional output is established from the output of the RF transmitter **206** of the data processing and transmitter unit **102** for transmission to the primary receiver unit **104**. In this manner, a data path is shown in FIG. **2** between the aforementioned unidirectional input and output via a dedicated link **209** from the analog interface **201** to serial communication section **205**, thereafter to the processor **204**, and then to the RF transmitter **206**. As such, in one embodiment, via the data path described above, the data processing and transmitter unit **102** is configured to transmit to the primary receiver unit **104** (FIG. **1**), via the communication link **103** (FIG. **1**), processed and encoded data signals received from the sensor unit **101** (FIG. **1**). Additionally, the unidirectional communication data path between the analog interface **201** and the RF transmitter **206** discussed above allows for the configuration of the data processing and transmitter unit **102** for operation upon completion of the manufacturing process as well as for direct communication for diagnostic and testing purposes.

(32) As discussed above, the transmitter processor **204** is configured to transmit control signals to the various sections of the data processing and transmitter unit **102** during the operation of the data processing and transmitter unit **102**. In one embodiment, the transmitter processor **204** also includes a memory (not shown) for storing data such as the identification information for the data processing and transmitter unit **102**, as well as the data signals received from the sensor unit **101**.

The stored information may be retrieved and processed for transmission to the primary receiver unit **104** under the control of the transmitter processor **204**. Furthermore, the power supply **207** may include a commercially available battery, which may be a rechargeable battery.

(33) In certain embodiments, the data processing and transmitter unit **102** is also configured such that the power supply section **207** is capable of providing power to the transmitter for a minimum of about three months of continuous operation, e.g., after having been stored for about eighteen months such as stored in a low-power (non-operating) mode. In one embodiment, this may be achieved by the transmitter processor **204** operating in low power modes in the non-operating state, for example, drawing no more than approximately 1 μA of current. Indeed, in one embodiment, a step during the manufacturing process of the data processing and transmitter unit **102** may place the data processing and transmitter unit **102** in the lower power, non-operating state (i.e., post-manufacture sleep mode). In this manner, the shelf life of the data processing and transmitter unit **102** may be significantly improved. Moreover, as shown in FIG. **2**, while the power supply unit **207** is shown as coupled to the processor **204**, and as such, the processor **204** is configured to provide control of the power supply unit **207**, it should be noted that within the scope of the present disclosure, the power supply unit **207** is configured to provide the necessary power to each of the components of the data processing and transmitter unit **102** shown in FIG. **2**.

(34) Referring back to FIG. **2**, the power supply section **207** of the data processing and transmitter unit **102** in one embodiment may include a rechargeable battery unit that may be recharged by a separate power supply recharging unit (for example, provided in the receiver unit **104**) so that the data processing and transmitter unit **102** may be powered for a longer period of usage time. Moreover, in one embodiment, the data processing and transmitter unit **102** may be configured without a battery in the power supply section **207**, in which case the data processing and transmitter unit **102** may be configured to receive power from an external power supply source (for example, a battery) as discussed in further detail below.

(35) Referring yet again to FIG. **2**, the temperature measurement section **203** of the data processing and transmitter unit **102** is configured to monitor the temperature of the skin near the sensor insertion site. The temperature reading is used to adjust the analyte readings obtained from the analog interface **201**. In certain embodiments, the RF transmitter **206** of the transmitter unit **102** may be configured for operation in the frequency band of approximately 315 MHz to approximately 322 MHz, for example, in the United States. In certain embodiments, the RF transmitter **206** of the transmitter unit **102** may be configured for operation in the frequency band of approximately 400 MHz to approximately 470 MHz. Further, in one embodiment, the RF transmitter **206** is configured to modulate the carrier frequency by performing Frequency Shift Keying and Manchester encoding. In one embodiment, the data transmission rate is about 19,200 symbols per second, with a minimum transmission range for communication with the primary receiver unit **104**.

(36) Referring yet again to FIG. **2**, also shown is a leak detection circuit **214** coupled to the guard electrode (G) **211** and the processor **204** in the transmitter unit **102** of the data monitoring and management system **100**. The leak detection circuit **214** in accordance with one embodiment of the present disclosure may be configured to detect leakage current in the sensor unit **101** to determine whether the measured sensor data are corrupt or whether the measured data from the sensor **101** is accurate. Exemplary analyte systems that may be employed are described in, for example, U.S. Pat. Nos. 6,134,461, 6,175,752, 6,121,611, 6,560,471, 6,746,582, and elsewhere, the disclosure of each of which are incorporated by reference for all purposes.

(37) FIG. **3** is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. **1** in accordance with one embodiment of the present disclosure. Referring to FIG. **3**, the primary receiver unit **104** includes an analyte test strip, e.g., blood glucose test strip, interface **301**, an RF receiver **302**, an input **303**, a temperature monitor section **304**, and a clock **305**, each of which is operatively coupled to a receiver processor **307**. As can be further seen from

the Figure, the primary receiver unit **104** also includes a power supply **306** operatively coupled to a power conversion and monitoring section **308**. Further, the power conversion and monitoring section **308** is also coupled to the receiver processor **307**. Moreover, also shown are a receiver serial communication section **309**, and an output **310**, each operatively coupled to the receiver processor **307**.

(38) In one embodiment, the test strip interface **301** includes a glucose level testing portion to receive a manual insertion of a glucose test strip, and thereby determine and display the glucose level of the test strip on the output **310** of the primary receiver unit **104**. This manual testing of glucose may be used to calibrate the sensor unit **101** or otherwise. The RF receiver **302** is configured to communicate, via the communication link **103** (FIG. **1**) with the RF transmitter **206** of the transmitter unit **102**, to receive encoded data signals from the transmitter unit **102** for, among others, signal mixing, demodulation, and other data processing. The input **303** of the primary receiver unit **104** is configured to allow the user to enter information into the primary receiver unit **104** as needed. In one aspect, the input **303** may include one or more keys of a keypad, a touch-sensitive screen, or a voice-activated input command unit. The temperature monitor section **304** is configured to provide temperature information of the primary receiver unit **104** to the receiver processor **307**, while the clock **305** provides, among others, real time information to the receiver processor **307**.

(39) Each of the various components of the primary receiver unit **104** shown in FIG. **3** is powered by the power supply **306** which, in one embodiment, includes a battery. Furthermore, the power conversion and monitoring section **308** is configured to monitor the power usage by the various components in the primary receiver unit **104** for effective power management and to alert the user, for example, in the event of power usage which renders the primary receiver unit **104** in sub-optimal operating conditions. An example of such sub-optimal operating condition may include, for example, operating the vibration output mode (as discussed below) for a period of time thus substantially draining the power supply **306** while the processor **307** (thus, the primary receiver unit **104**) is turned on. Moreover, the power conversion and monitoring section **308** may additionally be configured to include a reverse polarity protection circuit such as a field effect transistor (FET) configured as a battery activated switch.

(40) The serial communication section **309** in the primary receiver unit **104** is configured to provide a bi-directional communication path from the testing and/or manufacturing equipment for, among others, initialization, testing, and configuration of the primary receiver unit **104**. Serial communication section **104** can also be used to upload data to a computer, such as time-stamped blood glucose data. The communication link with an external device (not shown) can be made, for example, by cable, infrared (IR) or RF link. The output **310** of the primary receiver unit **104** is configured to provide, among others, a graphical user interface (GUI) such as a liquid crystal display (LCD) for displaying information. Additionally, the output **310** may also include an integrated speaker for outputting audible signals as well as to provide vibration output as commonly found in handheld electronic devices, such as mobile telephones presently available. In a further embodiment, the primary receiver unit **104** also includes an electro-luminescent lamp configured to provide backlighting to the output **310** for output visual display in dark ambient surroundings.

(41) Referring back to FIG. **3**, the primary receiver unit **104** in one embodiment may also include a storage section such as a programmable, non-volatile memory device as part of the processor **307**, or provided separately in the primary receiver unit **104**, operatively coupled to the processor **307**. The processor **307** may be configured to synchronize with a transmitter, e.g., using Manchester decoding or the like, as well as error detection and correction upon the encoded data signals received from the transmitter unit **102** via the communication link **103**.

(42) Periodic calibration of the sensor unit **101** (FIG. **1**) of an analyte monitoring system **100**, in some embodiments, may be required for accurate calculation of a user's analyte level. Calibration,

in some aspects, is used to ensure the analyte related data signals received at a transmitter unit **102** (and further transmitted to a receiver unit, such as the primary receiver unit **104**) are correctly converted to corresponding analyte levels. Exemplary calibration protocols, routines and techniques are described, for example, in U.S. Pat. No. 7,299,082, U.S. patent application Ser. No. 11/537,991 filed Oct. 2, 2006, U.S. patent application Ser. No. 12/363,706 filed Jan. 30, 2009, and in U.S. patent application Ser. No. 12/363,712 filed Jan. 30, 2009, the disclosures of each of which are herein incorporated by reference for all purposes.

(43) There are time periods where the sensor characteristics or the user's physiological condition renders the condition unsuitable for a sensor calibration event. For example, the sensor may be configured for periodic calibration, such as, after 2 hours after insertion, 10 hours after insertion, 12 hours after insertion, 24 hours after insertion, 48 hours after insertion, or 72 hours after insertion, or one or more combinations thereof. If a predetermined calibration event is triggered but a successful calibration does not result, after a certain time period (for example, a predetermined grace period during which to calibrate), the receiver unit may no longer display the monitored and processed glucose information.

(44) Other conditions may also result in rendering the condition unsuitable for sensor calibration including, but not limited to, detection of a failure mode of a sensor, sensor data values being outside a predetermined range, rate of change of sensor data values being above a predetermined threshold, a temperature measurement outside a predetermined range, or any combination thereof.

(45) FIG. **4** illustrates analyte sensor data processing in accordance with one embodiment of the present disclosure. Referring to FIG. **4**, a transmitter unit **102** (FIG. **1**) in operational contact with a sensor **101** receives analyte related sensor data (**410**) corresponding to a measured level of a biological fluid of the user. For example, the sensor **101** (FIG. **1**) may be an analyte sensor configured to detect and measure the concentration of an analyte in a biological fluid, such as the blood of a user. Upon receipt of the analyte related sensor data, the transmitter unit **102** further transmits the analyte related sensor data to a receiver unit, such as primary receiver unit **104** (FIG. **1**). It is to be noted that the reference to analyte related sensor data herein and throughout specification includes, for example, current signal received from the analyte sensor, as well as the current signal which has undergone predetermined data processing routines including, for example, filtering, clipping, digitizing, and/or encoding, and/or any other further processing and/or conditioning. In one aspect, the primary receiver unit **104** determines whether the sensor is calibrated and is in acceptable condition for further data processing (**420**). When sensor related conditions are unsuitable for calibration, the analyte related sensor data is stored (**450**) in a memory, for example, in the primary receiver unit **104**.

(46) Referring still to FIG. **4**, if the sensor data is calibrated and in condition for further data processing, the sensor data is further processed (**430**) and output for display (**440**) to a user on a display unit **310** (FIG. **3**) of the primary receiver unit **104**. In one embodiment, the display of the processed sensor data comprises a graphical representation of the processed sensor data. In other embodiments, the processed sensor data may be displayed as numerical values, visual indicators, auditory outputs, or combinations thereof. In one aspect, the processing routine described in conjunction with FIG. **4** is performed or executed in, for example, the transmitter unit **102**, the secondary receiver unit **106** (FIG. **1**), or the data processing terminal **105** (FIG. **1**) of the analyte monitoring system **100** (FIG. **1**) based on analyte data received from the sensor **101**.

(47) FIG. **5** illustrates analyte sensor data processing in accordance with one embodiment of the present disclosure. Referring to FIG. **5**, in one embodiment, transmitter unit **102** (FIG. **1**) receives analyte related sensor data (**510**) from a sensor **101** (FIG. **1**). Upon receipt of the analyte related sensor data, the transmitter unit **102** transmits the analyte related sensor data (or processed, digitized, and/or filtered signals) to the primary receiver unit **104** (FIG. **1**). The primary receiver unit **104** is configured to determine if calibration of the sensor data is suitable—that is, whether the conditions necessary for sensor calibration are met (**520**).

(48) Still referring to FIG. **5**, if it is determined that the sensor **101** is not calibrated or calibration condition for calibrating the sensor **101** is not met, in one aspect, the primary receiver unit stores the analyte related sensor data in a memory (**550**) and temporarily disables display of the sensor data (**560**) to the user (for example, if a calibration event has not occurred and the calibration grace period has expired). On the other hand, if the sensor **101** is calibrated, the sensor data is processed (**530**) by the primary receiver unit **104** and the processed sensor data is output to the user (**540**), for example via a display unit **310** (FIG. **3**) of the primary receiver unit **104**. In one aspect, the processing routine described in conjunction with FIG. **5** is performed or executed in, for example, the transmitter unit **102**, the secondary receiver unit **106**, or the data processing terminal **105** of the analyte monitoring system **100** based on analyte data received from the sensor **101** (FIG. **1**).
(49) In one aspect, the display or output of processed sensor data may be disabled if a required calibration event is unsuccessful over a permitted time period (for example, including a predetermined grace period measured from the scheduled calibration). Thereafter, upon successful calibration, the system resumes display of the processed and calibrated analyte sensor data. However, there may be a time period or a gap in the output display during which the necessary calibration did not occur in a timely manner. For example, as shown in FIG. **7**A, if sensor data is displayed as a graphical display, during time periods where the analyte monitoring system **100** was not properly calibrated, analyte related sensor data was not processed and/or displayed, resulting in a gap in the graphical display.
(50) FIG. **6** illustrates backfilling gaps in sensor data in one embodiment of the present disclosure. Referring to FIG. **6**, when a scheduled calibration event fails and the associated grace period for calibration does not occur, the output display of the processed, calibrated sensor data is disabled (**610**). Referring to FIG. **6**, once the system recovers after a successful calibration event, the calibrated sensor data is once again displayed (and stored). Furthermore, in one aspect, based on the parameters associated with the successful calibration, the previously unprocessed data during the display time out period may be retrieved (for example, the previously stored analyte related sensor signals during this period) and processed using calibration data, such as a sensitivity ratio for conversion of analyte related sensor data to analyte levels. For example, in one aspect, the subset of analyte related sensor data that were previously unprocessed or uncalibrated due to unsuccessful contemporaneous calibration may be processed using, for example, calibration data such as the sensitivity ratio determined from the most recent successful calibration event, and thereafter, the gap in output display illustrating the processed and calibrated signals may be filled.
(51) In one aspect, once successful calibration of the sensor data occurs, the calibration parameters from this calibration event may be used to process the sensor data during the period of disabled output or display (**620**). Upon successful processing of the sensor data during the period of disabled output, the processed sensor data during this time period is backfilled, or the gap in the processed continuous sensor data are filled in the display (**630**). By way of an example, FIGS. **7**A and **7**B illustrate the replacement of a period of unprocessed sensor data with corresponding backfilled processed sensor data, in one embodiment.
(52) In one embodiment, the backfilled processed sensor data is displayed immediately upon calculation. In another embodiment, the backfilled processed sensor data is not displayed immediately, but rather, after waiting a predetermined period of time. The backfilled processed sensor data may not be displayed immediately to avoid possible unnecessary or incorrect action by a user in response to the backfilled processed sensor data. In this manner, in one aspect, the user or a healthcare provider may be provided with a continuous set of analyte data from the analyte monitoring system without any gaps in the processed signals for further analysis and/or therapy management.
(53) In this manner, in accordance with the embodiments of the present disclosure, gaps in monitored analyte levels using an analyte monitoring system due to, for example, inability to promptly calibrate the sensor, system malfunction, sensor dislodging, signal errors associated with

the sensor, transmitter unit, receiver unit, and the like, or any other variables or parameters that result in the inability of the analyte monitoring system to display or output the real-time monitored analyte level, may be retrospectively filled or reprocessed so that the data gap is closed and the continuously monitored analyte level does not have any or substantially missing data. That is, in embodiments of the present disclosure, upon correction or rectification of the condition or conditions/parameters which resulted in the analyte monitoring system disabling the output results associated with the monitored real time analyte levels, the parameters associated with the correction or rectification may be used to retrospectively correct or process data or signals so that the missing gaps in analyte related data may be processed and backfilled.

(54) In this manner, advantageously, in aspects of the present disclosure, additional robustness may be provided to the user and/or the healthcare provider to improve therapy or health management decisions.

(55) In one embodiment, a method may include receiving sensor data from an analyte sensor of a sensor monitoring system, processing the received sensor data with time corresponding calibration data, outputting the processed sensor data, detecting one or more adverse conditions associated with the sensor monitoring system, disabling the output of the sensor data during an adverse condition time period, determining that the one or more detected adverse conditions is no longer present in the sensor monitoring system, retrieving the sensor data during the adverse condition time period, processing the retrieved sensor data during the adverse condition time period, and outputting the processed retrieved sensor data.

(56) In one aspect, outputting the processed sensor data may include displaying the sensor data in one or more of a graphical, numerical, pictorial, audible, vibratory, or one or more combinations thereof.

(57) The one or more detected adverse conditions may include one or more of a sensor instability condition, a calibration failure condition, or a monitoring system failure condition.

(58) The sensor instability condition may include one or more of an early signal attenuation condition of the sensor, sensor misposition error, sensor communication error, temperature measurement outside a predetermined range, or a combination thereof.

(59) The calibration failure condition may include one or more of an analyte level exceeding a predetermined threshold, a rate of change of analyte level exceeding a predetermined threshold, a signal error associated with the reference data, a data unavailability condition, or a combination thereof.

(60) Furthermore, the method may include storing the processed sensor data with the associated time information based on the analyte level detection time by the sensor.

(61) In another embodiment, a method may include detecting a condition unsuitable for calibration of an analyte sensor for a predetermined time period, disabling output of information associated with the analyte sensor, determining a successful calibration of the analyte sensor, retrieving one or more parameters associated with the successful calibration, processing sensor data during the time period of disabled output of information with the one or more parameters associated with the successful calibration, and displaying the processed sensor data for the time period of disabled information output.

(62) The sensor data may be analyte concentration data.

(63) The analyte concentration data may include blood glucose concentration data.

(64) The sensor data may be processed in substantially real-time.

(65) The condition unsuitable for calibration may include one or more of a failure mode of a sensor, sensor data outside a predetermined acceptable range, a rate of change of sensor data above a predetermined level, a requirement for calibration of a sensor, a temperature measurement outside a predetermined range, or any combination thereof.

(66) The processed sensor data for the time period of disabled information output may be displayed substantially immediately upon processing.

(67) The processed sensor data for the time period of disabled information output may be displayed only after waiting a predetermined period of time.
(68) In another embodiment, an apparatus may include an interface configured to receive sensor data, a first memory configured to store the received sensor data, a processor coupled to the memory and configured to process the stored sensor data, a second memory coupled to the processor and configured to store the processed sensor data, and a display unit coupled to the second memory and configured to display the processed sensor data, wherein the processor is further configured to detect a condition unsuitable for calibration of a sensor for a predetermined time period, disable display of processed sensor data, determine a successful calibration of the sensor, retrieve one or more parameters associated with the successful calibration, process the sensor data during the time period of disabled display of sensor data with the one or more parameters associated with the successful calibration, and display the processed sensor data for the time period of disabled information output.
(69) The sensor may be an analyte sensor.
(70) The analyte sensor may be a glucose sensor.
(71) The sensor data may correspond to analyte concentration data.
(72) The analyte concentration data may include blood glucose concentration data.
(73) Furthermore, the apparatus may be configured to process and display the sensor data substantially in real-time.
(74) In one aspect, the condition unsuitable for calibration may include one or more of a failure mode of a sensor, sensor data outside a predetermined acceptable range, a rate of change of sensor data above a predetermined level, a requirement for calibration of a sensor, a temperature measurement outside a predetermined range, or any combination thereof.
(75) The display unit may be configured to display the processed sensor data for the time period of disabled information output substantially immediately upon processing the sensor data.
(76) The display unit may be configured to display the processed sensor data for the time period of disabled information output only after waiting a predetermined period of time.
(77) Various other modifications and alterations in the structure and method of operation of this invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims

1. A glucose monitoring system comprising: a glucose sensor, a portion of which is configured to be positioned under skin of the user, wherein the glucose sensor comprises at least two electrodes, and wherein the glucose sensor is configured to sample a biological fluid of the user to provide sensor data; a transmitter unit coupled to the glucose sensor, the transmitter unit comprising a power supply, a processor of the transmitter unit, memory of the transmitter unit, and a radio frequency transceiver of the transmitter unit, wherein the transmitter unit is configured to: receive the sensor data from the glucose sensor, process the sensor data using calibration data to provide processed sensor data, wherein the calibration data comprises data associated with a sensitivity of the glucose sensor, and wherein the processed sensor data is stored in the memory of the transmitter unit, and transmit the processed sensor data over a Bluetooth wireless communication link using the radio frequency transceiver of the transmitter unit; and a primary receiver unit comprising a processor of the primary receiver unit, memory of the primary receiver unit, a radio frequency transceiver of the primary receiver unit, an antenna, and a display, wherein the primary receiver

unit is configured to: receive, using the antenna and the radio frequency transceiver of the primary receiver unit, the processed sensor data over the Bluetooth wireless communication link, output to the display of the primary receiver unit, a numerical value based on the processed sensor data, and output to the display of the primary receiver unit, a first line graph that is a continuous depiction of the processed sensor data over time, wherein the transmitter unit and at least a portion of the glucose sensor are disposed within a single integrated housing, wherein the glucose monitoring system is configured to detect an adverse condition, wherein the adverse condition comprises a signal error associated with the transmitter unit, wherein the adverse condition results in the primary receiver unit displaying a data gap such that the first line graph displayed on the primary receiver unit has an end corresponding to a time associated with a start of the adverse condition, wherein, during a time period corresponding to the adverse condition, processed sensor data is stored in the memory of the transmitter unit, wherein the primary receiver unit is configured to output to the display, after the adverse condition is corrected, processed sensor data for the time period corresponding to the adverse condition such that the data gap is backfilled, and wherein the processed sensor data for the time period corresponding to the adverse condition that is outputted to the display after the adverse condition is corrected comprises a second line graph having a first end corresponding to the time associated with the start of the adverse condition and a second end corresponding to a time associated with an end of the adverse condition.

2. The glucose monitoring system of claim 1, wherein the first line graph and the second line graph are outputted to a same graph comprising a first axis having a time unit of measurement and a second axis having a glucose concentration unit of measurement.

3. The glucose monitoring system of claim 2, wherein the primary receiver unit is further configured to display the second line graph immediately after correction of the adverse condition.

4. The glucose monitoring system of claim 2, wherein the primary receiver unit is further configured to wait a predetermined period of time after correction of the adverse condition before displaying the second line graph.

5. The glucose monitoring system of claim 1, wherein the at least two electrodes comprise a working electrode and a counter electrode.

6. The glucose monitoring system of claim 1, wherein the transmitter unit, the primary receiver unit, or both is further configured to store time information associated with the adverse condition.

7. The glucose monitoring system of claim 1, wherein the time period associated with the adverse condition comprises at least one hour.

8. The glucose monitoring system of claim 1, wherein the glucose monitoring system is further configured for periodic calibration, and wherein the calibration data is based at least in part on glucose reference data received after the portion of the glucose sensor has been positioned under the skin of the user.

9. The glucose monitoring system of claim 8, wherein the glucose monitoring system is further configured for calibration twelve hours after the portion of the glucose sensor has been positioned under the skin of the user.

10. The glucose monitoring system of claim 1, wherein the transmitter unit is configured to transition from a low-power mode to an operating mode, and wherein the transmitter unit consumes more power from the power supply in the operating mode than in the low-power mode.

11. The glucose monitoring system of claim 10, wherein the power supply of the transmitter unit is configured to provide power for about three months of continuous operation.

12. The glucose monitoring system of claim 1, further comprising a secondary receiver unit, wherein the secondary receiver unit is configured to receive processed sensor data.

13. The glucose monitoring system of claim 12, wherein the secondary receiver unit is configured to include a limited number of functions as compared with the primary receiver unit.

14. The glucose monitoring system of claim 13, wherein the secondary receiver unit is a watch.

15. The glucose monitoring system of claim 1, wherein the adverse condition further comprises a

condition in which the primary receiver unit is outside a communication range of the transmitter unit.

16. A glucose monitoring system comprising: a glucose sensor, a portion of which is configured to be positioned under skin of the user, wherein the glucose sensor comprises at least two electrodes, and wherein the glucose sensor is configured to sample a biological fluid of the user to provide sensor data; a transmitter unit coupled to the glucose sensor, the transmitter unit comprising a power supply, a processor of the transmitter unit, memory of the transmitter unit, and a radio frequency transceiver of the transmitter unit, wherein the transmitter unit is configured to: receive the sensor data from the glucose sensor, process the sensor data using calibration data to provide processed sensor data, wherein the calibration data comprises data associated with a sensitivity of the glucose sensor, and wherein the processed sensor data is stored in the memory of the transmitter unit, and transmit the processed sensor data over a Bluetooth wireless communication link using the radio frequency transceiver of the transmitter unit; and a primary receiver unit comprising a processor of the primary receiver unit, memory of the primary receiver unit, a radio frequency transceiver of the primary receiver unit, an antenna, and a display, wherein the primary receiver unit is configured to: receive, using the antenna and the radio frequency transceiver of the primary receiver unit, the processed sensor data over the Bluetooth wireless communication link, output to the display of the primary receiver unit, a numerical value based on the processed sensor data, and output to the display of the primary receiver unit, a first line graph that is a continuous depiction of the processed sensor data over time, wherein the transmitter unit and at least a portion of the glucose sensor are disposed within a single integrated housing, wherein the glucose monitoring system is configured to detect an adverse condition, wherein the adverse condition comprises a signal error associated with the primary receiver unit, wherein the adverse condition results in the primary receiver unit displaying a data gap such that the first line graph displayed on the primary receiver unit has an end corresponding to a time associated with a start of the adverse condition, wherein, during a time period corresponding to the adverse condition, processed sensor data is stored in the memory of the transmitter unit, wherein the primary receiver unit is configured to output to the display, after the adverse condition is corrected, processed sensor data for the time period corresponding to the adverse condition such that the data gap is backfilled, and wherein the processed sensor data for the time period corresponding to the adverse condition that is outputted to the display after the adverse condition is corrected comprises a second line graph having a first end corresponding to the time associated with the start of the adverse condition and a second end corresponding to a time associated with an end of the adverse condition.

17. The glucose monitoring system of claim 16, wherein the primary receiver unit is further configured to display the second line graph immediately after correction of the adverse condition.

18. The glucose monitoring system of claim 16, wherein the primary receiver unit is further configured to wait a predetermined period of time after correction of the adverse condition before displaying the second line graph.

19. The glucose monitoring system of claim 16, further comprising a secondary receiver unit, wherein the secondary receiver unit is configured to receive processed sensor data, and wherein the secondary receiver unit is a watch.

20. The glucose monitoring system of claim 16, wherein the adverse condition further comprises a condition in which the primary receiver unit is outside a communication range of the transmitter unit.

21. The glucose monitoring system of claim 16, wherein the time period associated with the adverse condition comprises at least one hour.

22. A glucose monitoring system comprising: a glucose sensor, a portion of which is configured to be positioned under skin of the user, wherein the glucose sensor comprises at least a working electrode and a counter electrode, wherein the glucose sensor is configured to sample a biological fluid of the user to provide sensor data; a transmitter unit coupled to the glucose sensor, the

transmitter unit comprising a power supply, a processor of the transmitter unit, memory of the transmitter unit, and a radio frequency transceiver of the transmitter unit, wherein the transmitter unit is configured to: receive the sensor data from the glucose sensor and store the sensor data in the memory of the data processing and transmitter unit, process the sensor data using calibration data to provide processed sensor data, wherein the calibration data comprises data associated with a sensitivity of the glucose sensor, and wherein the processed sensor data is stored in the memory of the transmitter unit, and transmit the processed sensor data over a Bluetooth wireless communication link using the radio frequency transceiver of the transmitter unit; and a primary receiver unit comprising a processor of the primary receiver unit, memory of the primary receiver unit, a radio frequency transceiver of the primary receiver unit, an antenna, and a display, wherein the primary receiver unit is configured to: receive, using the antenna and the radio frequency transceiver of the primary receiver unit, the processed sensor data over the Bluetooth wireless communication link, output to the display of the primary receiver unit, a numerical value based on the processed sensor data, and output to the display of the primary receiver unit, a first line graph that is a continuous depiction of the processed sensor data over time, wherein the transmitter unit and at least a portion of the glucose sensor are disposed within a single integrated housing, wherein the glucose monitoring system is configured to detect an adverse condition, wherein the adverse condition comprises one or more sensor data values being outside a predetermined range, wherein the adverse condition results in the primary receiver unit displaying a data gap such that the first line graph displayed on the primary receiver unit has an end corresponding to a time associated with a start of the adverse condition, wherein, during a time period corresponding to the adverse condition, sensor data is stored in the memory of the data processing and transmitter unit, wherein the primary receiver unit is configured to output to the display, after the adverse condition is corrected, processed sensor data for the time period corresponding to the adverse condition such that the data gap is backfilled, wherein the processed sensor data for the time period corresponding to the adverse condition that is outputted to the display after the adverse condition is corrected comprises a second line graph having a first end corresponding to the time associated with the start of the adverse condition and a second end corresponding to a time associated with an end of the adverse condition, and wherein the first line graph and the second line graph are outputted to a same graph comprising a first axis having a time unit of measurement and a second axis having a glucose concentration unit of measurement.

23. The glucose monitoring system of claim 22, wherein the primary receiver unit is further configured to display the second line graph immediately after correction of the adverse condition.

24. The glucose monitoring system of claim 22, wherein the primary receiver unit is further configured to wait a predetermined period of time after correction of the adverse condition before displaying the second line graph.

25. The glucose monitoring system of claim 22, wherein the transmitter unit and at least a portion of the glucose sensor are disposed within a single integrated housing.

26. The glucose monitoring system of claim 22, further comprising a secondary receiver unit, wherein the secondary receiver unit is configured to receive processed sensor data.

27. The glucose monitoring system of claim 26, wherein the secondary receiver unit is a watch.

28. The glucose monitoring system of claim 22, wherein the time period associated with the adverse condition comprises at least one hour.